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ABSTRACT OF THE DISSERTATION 
COMPREHENSIVE FORENSIC TOXICOLOGICAL ANALYSIS OF DESIGNER 
DRUGS 
by 
Madeleine Jean Swortwood 
Florida International University, 2013 
Miami, Florida 
Professor Anthony DeCaprio, Major Professor 
New designer drugs are constantly emerging onto the illicit drug market and it is 
often difficult to validate and maintain comprehensive analytical methods for accurate 
detection of these compounds.  Generally, toxicology laboratories utilize a screening 
method, such as immunoassay, for the presumptive identification of drugs of abuse. 
When a positive result occurs, confirmatory methods, such as gas chromatography (GC) 
or liquid chromatography (LC) coupled with mass spectrometry (MS), are required for 
more sensitive and specific analyses.  In recent years, the need to study the activities of 
these compounds in screening assays as well as to develop confirmatory techniques to 
detect them in biological specimens has been recognized.  Severe intoxications and 
fatalities have been encountered with emerging designer drugs, presenting analytical 
challenges for detection and identification of such novel compounds.  The first major task 
of this research was to evaluate the performance of commercially available 
immunoassays to determine if designer drugs were cross-reactive.  The second major task 
was to develop and validate a confirmatory method, using LC-MS, to identify and 
quantify these designer drugs in biological specimens.   
vi 
Cross-reactivity towards the cathinone derivatives was found to be minimal.  
Several other phenethylamines demonstrated cross-reactivity at low concentrations, but 
results were consistent with those published by the assay manufacturer or as reported in 
the literature.  Current immunoassay-based screening methods may not be ideal for 
presumptively identifying most designer drugs, including the “bath salts.”  For this 
reason, an LC-MS based confirmatory method was developed for 32  compounds, 
including eight cathinone derivatives, with limits of quantification in the range of 1-10 
ng/mL.  The method was fully validated for selectivity, matrix effects, stability, recovery, 
precision, and accuracy.  In order to compare the screening and confirmatory techniques, 
several human specimens were analyzed to demonstrate the importance of using a 
specific analytical method, such as LC-MS, to detect designer drugs in serum as 
immunoassays lack cross-reactivity with the novel compounds.  Overall, minimal cross-
reactivity was observed, highlighting the conclusion that these presumptive screens 
cannot detect many of the designer drugs and that a confirmatory technique, such as the 
LC-MS, is required for the comprehensive forensic toxicological analysis of designer 
drugs.        
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1. INTRODUCTION 
1.1 Statement of the Problem 
The “designer drugs” are analogs or derivatives of controlled substances that are 
sold on the street in an attempt to circumvent the legal restrictions placed on scheduled 
drugs (www.dea.gov).  New designer drugs are constantly emerging onto the illicit drug 
market and it is difficult to validate and maintain comprehensive analytical methods for 
accurate detection of these compounds.  Chemical modifications in these substances can 
be very subtle, leading to virtually unlimited structural variation.  As a consequence, 
there are many hundreds of such entities that have been identified to date.  Generally, 
forensic toxicology laboratories utilize a screening method, such as immunoassay, for the 
presumptive identification of drugs of abuse.  When a positive result occurs, confirmatory 
methods, such as gas chromatography (GC) or liquid chromatography (LC) coupled with 
mass spectrometry (MS), are required for more sensitive and specific qualitative and 
quantitative analyses.  In recent years, the need to study the activities of these compounds 
in screening assays as well as to develop confirmatory techniques to detect them in 
biological specimens has been recognized.(1) 
Designer drugs have been a major topic of concern in Europe for some time and 
this issue has also become increasingly important in the United States.  The United States 
Drug Enforcement Agency (DEA) has scheduled, emergency scheduled, and even 
unscheduled a number of these compounds (www.dea.gov).  For example, DEA recently 
scheduled 26 designer drugs in the cathinone, phenethylamine, and synthetic cannabinoid 
classes under the Synthetic Drug Abuse Prevention Act of 2012.  In addition to the 
federal legislation, 43 states and Puerto Rico have outlawed synthetic cathinones as of 
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November 2012, according to the National Conference of State Legislatures (NCSL).  
Many of the states have enacted laws more stringent than those in place at the federal 
level, with some states banning cathinones as a general class of compounds.   Most 
recently, severe intoxications and fatalities have been reported with new and emerging 
designer drugs, presenting challenges for toxicologists involved with the detection and 
identification of such novel compounds.(1-19) 
1.2 Rationale for Research 
On the basis of the above data, there is a critical need in the field of forensic 
toxicology for reliable screening assays for multiple designer drugs, in addition to 
analytical methods optimized for comprehensive screening and confirmation of such 
drugs in a variety of human specimens for both ante- and post-mortem investigation.  A 
major goal of the research presented here was to evaluate the performance of 
commercially available screening immunoassays for detecting a wide range of designer 
drugs.  Since each manufacturer is likely to employ different antibodies, specificity for 
individual drugs cannot always be predicted or compared among other types of 
immunoassays (e.g., EMIT), different matrices (i.e., meconium, whole blood, oral fluid), 
or different manufacturers.  Regardless of any cross-reactivity that may occur, it is crucial 
that the forensic analytical toxicology community be made aware of the results, as 
screening techniques are currently limited for designer drugs, particularly the cathinone 
derivatives.   
In addition, it was also imperative to develop a MS confirmatory assay capable of 
rapid analysis of multiple designer drugs in a single run with high specificity at trace (i.e., 
parts per trillion to low parts per billion) levels.  In order to achieve this goal and confirm 
3 
cross-reactivity findings, a rapid, sensitive, and specific LC-MS analytical method was 
also developed.  It is anticipated that successful achievement of these goals will provide 
working forensic toxicology laboratories with important new data and tools for analysis 
of this class of drugs.   
Two primary hypotheses were tested in this project: 1) Some amphetamine-like 
designer compounds would not be detected using conventional assays, even when 
multiple immunoassay platforms were utilized (i.e., false negatives) and 2) some designer 
compounds would be detected in assays that theoretically target only amphetamine and 
methamphetamine (i.e., false positives).  In a working toxicology laboratory, a negative 
result as in (1) would generally not be further analyzed or confirmed with other methods, 
with the result that the drugs may be overlooked.  In contrast, a positive result as in (2) 
would trigger a confirmatory analysis, although an unknown designer drug would 
generally not be identified without proper reference standards or a comprehensive 
chromatographic method.  A focus was placed on amphetamine or 
methamphetamine/MDMA assays, as one or both of these types of assays are used in 
routine drug screens by a majority of laboratories.  Since presumptive methods, like 
ELISA and EMIT, are the first line of screening methods for detecting drugs of abuse, it 
was necessary to understand how these important drugs can be detected, if at all, by 
currently available immunoassays, even where cross-reactivity is not expected.       
1.3 Significance of Study 
The comprehensive study has applicability to forensic science, toxicology, law 
enforcement, and clinical medicine.  The research addresses issues of ultra-trace analysis, 
multiple-analyte samples, detection of novel drugs of abuse across different classes, and 
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cross-reactivities of such drugs in widely used immunoassays.  A comprehensive 
confirmatory analytical method for the identification of at least 30 designer drug entities 
in a short analysis period was developed.   
For the completion of the research, drugs were chosen based on prevalence in 
literature reports, DEA schedule, and availability as standards.  Focus was placed on 
cathinone derivatives, or “bath salts,” as their occurrence in society has been on the rise.  
Table 1 details the names and abbreviations for the 32 analytes chosen for inclusion in 
the study.  Additional information, including class and structure, can be found in 
Appendix 1. 
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Table 1: Designer Drug Abbreviations and Chemical Names 
Abbreviation or Common Name Chemical Name 
2C-B 2,5-dimethoxy-4-bromophenethylamine 
2C-E 2,5-dimethoxy-4-ethylphenethylamine 
2C-I 2,5-dimethoxy-4-iodophenethylamine 
2C-T-4 2,5-dimethoxy-4-(i)-propylthiophenethylamine 
2C-T-7 2,5-dimethoxy-4-(n)-propylthiophenethylamine 
4-FMC, Flephedrone 4-fluoromethcathinone 
4-MEC 4-methylethcathinone 
4-MMC, Mephedrone 4-methylmethcathinone  
5-MeO-DiPT 5-methoxy-diisopropyltryptamine 
5-MeO-DMT 5-methoxy-dimethyltryptamine 
AMT α-methyltryptamine 
bk-MBDB, Butylone 3,4-methylenedioxyethcathinone 
bk-MDMA, Methylone 3,4-methylenedioxymethcathinone 
bk-PMMA, PMMC, Methedrone, 4-methoxymethcathinone 
BZP benzylpiperazine 
Cathinone α-aminopropiophenone 
DBZP dibenzylpiperazine 
DMT dimethyltryptamine 
DOB 2,5-dimethoxy-4-bromoamphetamine 
DOET 2,5-dimethoxy-4-ethylamphetamine 
DOM 2,5-dimethoxy-4-methylamphetamine 
mCPP 3-chlorophenylpiperazine 
MDA 3,4-methylenedioxyamphetamine 
MDEA 3,4-methylenedioxyethylamphetamine 
MDMA, Ecstasy 3,4-methylenedioxymethamphetamine 
MDPV 3,4-methylenedioxypyrovalerone 
Methcathinone 2-methylaminopropiophenone 
TFMPP 3-trifluoromethylphenylpiperazine 
TMA 3,4,5-trimethoxyamphetamine 
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In order to fully test the proposed hypotheses, the research was divided into three 
major tasks.   
1.3.1 Task 1 - Determination of cross-reactivity of designer drugs 
In order to determine if structural analogs of drugs of abuse can be detected by 
immunoassays, cross-reactivity must be determined to examine if false positives or false 
negatives occur.  The current report details the design and results of a comprehensive 
study to examine cross-reactivity of thirty designer drugs in both serum and urine 
amongst 18 commercial immunoassays. 
1.3.2 Task 2 - Development of a comprehensive LC-MS method  
Since immunoassays are employed as presumptive, screening methods, a 
comprehensive analytical method was developed to confirm and quantify any drugs 
present in the samples.  In addition, the method was fully validated according to accepted 
analytical method development practices.     
1.3.3 Task 3 - Application of the developed techniques to forensic samples   
In forensic science, one of the most important tasks in regard to method 
development is the application.  In Task 3, forensic specimens were analyzed by both 
immunoassays and the confirmatory LC-MS method.  The dual-analysis allowed for true 
comparison of the two techniques (immunoassay and LC-MS) as well as assessment of 
the comprehensive LC-MS method when applied towards forensic case samples. 
7 
2. BACKGROUND 
2.1 Designer Drugs 
A designer drug is a compound which is psychotropic in nature and can be a 
synthetically altered natural compound, a structural modification of an existing 
xenobiotic, or a new chemical entirely.(20)  The term “designer drug” was first coined by 
Dr. Gary Henderson in the 1980s when fentanyl analogs began creeping into the drug 
market as “China White” heroin after passage of the Comprehensive Drug Abuse 
Prevention and Control Act of 1970.(21)  In general, designer drugs are structural analogs 
of Drug Enforcement Agency (DEA) Schedule I and II substances that are synthesized to 
mimic the effects of scheduled compounds and to avoid the provisions of drug laws.(22)  
Over the past decade, hundreds of such compounds have flooded the illicit drug market 
under the terms “designer drugs” or “research chemicals.”  In addition to the legal issues, 
these structurally related drugs often carry unknown safety profiles, a high potential for 
abuse, high potency, and serious potential health consequences, especially when ingested 
unknowingly.  Easy access via the internet has made such “designer drugs” more 
available to the general public. 
8Figure 1: Designer Drug Classes (20) 
Structures of most of the designer stimulant compounds fall into three major 
classes: phenethylamines, tryptamines, and piperazines, as seen in Figure 1.(20) The β-
keto-phenethylamine derivatives, analogs of cathinone, have been on the rise in the last 
few years, often sold as “bath salts” or “plant food” over the internet or in head 
shops.(23,24) Cathinone itself is a Schedule I drug occurring naturally in the leaves of the 
khat bush.  Another popular group of emerging designer drugs includes synthetic 
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cannabinoids, originally sold as “K2” or “Spice” as “legal” alternatives to marijuana.  In 
addition, previously available tryptamines such as α-methyltryptamine and 5-
methoxydiisopropyltryptamine (“Foxy”) have enjoyed resurgence and have been linked 
to several deaths in recent years.(6,25)  Trifluoromethylphenylpiperazine, once banned by 
the DEA, and benzylpiperazine, often found in combination with each other, have also 
been cited in several cases.(2)  While severe intoxications and even fatalities are not 
uncommon with abuse of these substances, they can be difficult to identify from a 
forensic analytical standpoint because of the large number of potential structures, the 
constant introduction of novel compounds, inadequate accessibility to standards, and the 
generally limited frequency of occurrences.(26)  Most importantly, there is a lack of 
comprehensive analytical methods available for detection of these compounds, either as 
screening techniques or for quantification purposes. 
2.2 Presence in Society 
During the 1990s, detailed user reports and steps for manufacturing hundreds of 
designer drugs were published by a former DEA-licensed chemist, Dr. Alexander 
Shulgin.  “Phenethylamines I Have Known and Loved” (PiHKAL) and “Tryptamines I 
Have Known and Loved” (TiHKAL) allowed drug users and manufacturers to have 
formulas at their fingertips.  As the use of the internet grew, additional resources, such as 
the website Erowid.org, offered similar forums. 
The American Association of Poison Control Centers (AAPCC) was the first to 
ring the alarm about “bath salts.”  In 2011 alone, their 57 call centers received over 6,000 
calls about exposures to these compounds, followed by almost 3,000 calls in 2012 
(aapcc.org).  The AAPCC has noted that the average users are in their twenties, but they 
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have received calls for children as young as 6 years old and adults as old as 59 years of 
age.  The merchandise, disguised as household products, was sold under brand names 
such as “Bliss”, “Cloud Nine”, “Ivory Wave”, and “Vanilla Sky” as powders in small foil 
packages (globaldrugpolicy.org).  In addition to these formulations, cathinone derivatives 
have also appeared in Ecstasy tablets after a worldwide shortage of MDMA precursors 
transpired in early 2008.(27)   
In October 2011, the DEA placed three of the most common compounds 
(methylone, mephedrone, and MDPV) into Schedule I as an emergency action.  In July of 
2012, President Obama signed the Synthetic Drug Abuse Prevention Act into law, 
permanently scheduling mephedrone, MDPV, and the 2C series of analogs, among other 
compounds, as Schedule I drugs.   
Although the street products are clearly labeled “not for human consumption,” the 
most common routes of administration are snorting, smoking, injecting, or swallowing 
(dea.gov).  With possible high potencies, the number of intoxications and lethal 
overdoses is rather large, especially when users also ingest their typical dose of another 
drug, such as Ecstasy.  The physiological and psychological effects of many of these 
substances somewhat mimic those of amphetamine, methamphetamine, and Ecstasy: 
increased energy, empathy, and extroversion.(24)  In addition, users may also experience 
multiple adverse effects, including hyperthermia, palpitations, agitation, headache, 
nausea, and vomiting.(24)  Furthermore, chronic users in online drug forums often discuss 
adding additional drugs, such as ibuprofen or Xanax (alprazolam) to combat these 
undesirable effects.  Many individuals have presented to emergency departments and 
hospitals with severe intoxications.  Reports have characterized the more dangerous 
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effects, including suicidal and homicidal ideations(12), psychosis(4,16), acute kidney 
injury(13,28), multi-organ failure(29), seizures(18), and Serotonin Syndrome(18).  With regard 
to fatal intoxications, case reports include cause of death such as disseminated 
intravascular coagulation(30,31), anoxic encephalopathy(31), cardiac arrest(31), acute kidney 
failure(32), and lethal Serotonin Syndrome.(11)             
2.3 Analysis of Drugs of Abuse in Biological Specimens 
Currently, there are established approaches for the detection of drugs of abuse in 
forensic toxicological specimens.  In the analysis of drugs of abuse, blood and urine have 
become the most commonly used human sample matrices(33), while only a few groups 
incorporate hair(34-36) or oral fluid.(37,38)  Blood is often the matrix of choice because it is 
easy to obtain and because of its applicability to both ante- and post-mortem samples.  
Blood (plasma, serum, or whole) has been utilized in various studies for the detection of 
amphetamines, tryptamines, piperazines, and major metabolites for purposes of drug 
screening, confirming driving under the influence of drugs (DUID), and examining road 
fatalities.(39,40,41,42)  Alternatively, hair, oral fluid, and exhaled breath have been examined 
but are less commonly encountered because of extraction complications, difficulty in 
obtaining samples, or lack of validation.(43-45)  In cases of DUI, blood is often the matrix 
of choice as it may correlate with impairment as well.(42,46)  The disadvantages of blood 
include the applicability to only short-term or recent drug use, a limited window of 
detection, and legal difficulties in obtaining blood from people suspected of drug 
abuse.(47) 
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As a way of sample clean-up and preparation, solid-phase extraction (SPE) is 
commonly used.  Solid-phase extraction is advantageous over liquid-liquid extraction 
because it is less costly, smaller amounts of solvent are used, and because it can be fully 
automated.(48-50)  Proper extraction is vital for limited sample sizes as well as for the 
analysis of multiple, chemically diverse analytes within one specimen.(51)  Pre-
concentration utilizing SPE allows for enhanced method sensitivity.(52)  However, matrix 
effects may hinder solid-phase extractions if incompatible cartridge chemistry is 
selected.(53) 
In routine toxicology casework, a screening technique, usually presumptive such 
as an immunological screen, is employed to identify specific analytes or a class of 
analytes.  Additional, more specific methods, including chromatographic separation, are 
employed to confirm positive findings.  Ultimately, quantitative results may also be 
necessary.   
2.3.1 Presumptive techniques 
Historically, color tests and thin-layer chromatography may have been used to 
presumptively identify drugs of abuse after simple extraction.(54)  Currently, in terms of 
drug screens, immunoassays are the gold standard for presumptively detecting drugs of 
abuse in biological specimens.(55)  These screens work well with blood but are not ideal 
for unclassified substances as each kit is designed only for a class of structures based on 
antigen-antibody interactions.(56)  Commercial assays are advantageous due to their 
general availability, quick analysis time, ease of automation, and sensitivity.  However, 
disadvantages include deficits in cross-reactivity data, a lack of specificity for some tests, 
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and labor intensiveness.(57-60)  While different assays are useful for detecting different 
types of drugs in forensic toxicology, false positives may occur.  In addition, positives 
still require confirmation by a chromatographic technique, and multiple classes of drugs 
cannot be detected and identified by one single test.(61) 
2.3.1.1 ELISA 
Enzyme-linked immunosorbent assays can be designed for a variety of 
biochemistry-related applications depending on the targeted antigen.  The technology is 
based on antibodies produced to bind to specific antigens.  The most popular type of 
ELISA, the direct competitive assay design, uses a plastic microtiter plate (96-well 
plates) coated with antibodies.(62)  The antibodies can be mono- or polyclonal in nature.  
Generally, monoclonal antibodies are more specific to a single antigen while polyclonal 
antibodies are capable of binding to a broader range of antigens.  These heterogeneous 
assays can be applied to a variety of liquid biological specimens, including whole blood, 
serum, oral fluid, or urine.      
In the analysis of drugs of abuse in biological specimens, several commercial 
manufacturers have designed antibodies and reagents for the detection of the most 
common classes of compounds, including amphetamines, barbiturates, benzodiazepines, 
benzoylecgonine (a cocaine metabolite), opiates, THC, and synthetic cannabinoids.  Very 
few kits have, as of yet, been targeted towards synthetic cathinone derivatives.  In 
general, these kits are packaged with all of the materials necessary, including a 96-well 
plate pre-coated with the antibodies.  In a typical ELISA, the sample is added to the well, 
followed by a drug-enzyme conjugate and a short incubation time.  Usually, horseradish 
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peroxidase (HRP) is the enzyme utilized in these assays for the color generating reaction.  
A wash step removes any materials (drug or drug-enzyme conjugate) that did not bind to 
the antibodies.  A substrate, usually TMB (3,3’,5,5’-tetramethylbenzidine), is added and 
reacts with the drug-enzyme conjugate to produce a colored product.  The absorbance is 
measured at a specified wavelength.  The more drug that is present in the sample, the less 
of the conjugate that will bind, leading to less color produced.  The absorbance values are 
then compared to positive and negative controls to determine positivity.  The ELISA 
process is represented graphically in Figure 2.  
 
Figure 2: Step by Step Process of an ELISA 
Adapted from neogen.com 
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Since the development of antibodies is a lengthy process, it is difficult for 
manufacturers of immunoassays to constantly develop assays to target the ever-changing 
designer drugs on the market today.  For this reason, it is important to understand the 
extent of cross-reactivity of designer drugs in current immunoassays, as will be discussed 
in Chapter 3.  
2.3.1.2 EMIT 
Enzyme multiplied immunoassay technique (EMIT) is a screening technique 
applied to the analysis of drugs in serum or metabolites in urine.(63)  This homogeneous 
assay is based on the ability of antibodies to inhibit the activity of a drug-enzyme 
conjugate.(64)  The enzyme employed is Glucose-6-phosphate dehydrogenase (G6PDH).  
If drug is present in the sample, it will bind to the antibodies and displace the drug-
enzyme conjugate, leading to increased enzyme activity, as seen in Figure 3.  The 
reaction rate, dependent on drug concentration in the sample, is monitored at 340 nm to 
detect the formation of NADH (reduced nicotinamide adenine dinucleotide).(64)  Glucose-
6-phosphate dehydrogenase G6PDH converts NAD+ (oxidized nicotinamide adenine 
dinucleotide) to NADH, resulting in an absorbance change.(64)  The EMIT technology is a 
simplified protocol and easily adapted to automation.  Enzyme multiplied immunoassays 
also offer significant sensitivity increases over heterogeneous assays like ELISA.(64)  
However, like ELISA, lengthy research is required to develop antibodies that not only 
offer specificity and affinity to the target but also inhibition of the drug-enzyme 
conjugate.  Today, Syva, a division of Siemens, offers the most popular assays of this 
nature for the detection of drug metabolites in urine.  
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Figure 3: Diagram of an EMIT system (65) 
Like ELISA, assays have been developed by Syva for common drugs of abuse, 
including amphetamines, barbiturates, benzodiazepines, benzoylecgonine, Ecstasy, 
opiates, and THC.  There are no assays yet available for synthetic cathinones.  For 
EMITs, it is also important to understand cross-reactivity using the current platforms, as 
specific assays for such designer drugs is not yet available, as will be discussed further in 
Chapter 3.        
2.3.2 Confirmatory techniques 
After presumptive screens are employed, positive results are confirmed, generally 
by chromatographic techniques such as GC-MS or LC-MS, in order to accurately identify 
and, if necessary, quantify the compounds present.  Since many of the designer drugs 
may not be detected by immunoassay screens, confirmatory techniques are necessary to 
fully characterize biological specimens when screening for these drugs.  Even when using 
MS-based screening techniques, some of the newer designer drugs may be overlooked, 
either because reference spectra are not available or because single ion monitoring (SIM) 
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or multiple reaction monitoring (MRM) methods may miss the typical fragments of 
certain compounds.(66)  For these reasons, it is important to expand and improve upon 
current analytical methods for comprehensive screening and confirmation of designer 
drugs.  
2.3.2.1 GC-MS 
Gas chromatography-mass spectrometry is a widely used analytical technique for 
the detection and quantification of a vast range of drugs in forensic toxicology.  Gas 
chromatography-mass spectrometry requires relatively volatile analytes, giving rise to the 
need for the selective extraction of the drugs from the biological matrix of choice and, 
often, subsequent derivatization prior to GC analysis.  Although several GC-MS methods 
have been published for the simultaneous analysis of a number of designer drugs 
belonging to different structural classes(67-69) most of the published literature focuses on 
the detection of single drugs and their associated metabolites.(70-74) The drug-specific 
method approach is a consequence of the continuing appearance of novel drug analogs on 
the illicit market.  Some research groups have developed methods for simultaneous 
detection of a small number of the most frequently encountered designer drugs,(75-79) 
while others have focused on creating GC-MS databases of designer and other drugs of 
abuse.(80,81)  A two-dimensional GC-MS method for the achievement of higher 
chromatographic resolution and selectivity has also been reported.(82)  Aside from 
detection of designer drugs in biological specimens, GC-MS can also be applied as an 
analytical technique in studies exploring the metabolism of these drugs.(83)  Several 
reviews on the analysis of phenethylamine, tryptamine, piperazine and cathinone-related 
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designer drug analogs have been published in recent years,(42,84) but comprehensive GC-
MS screening methods spanning all of these drug classes are rare.   
The three most commonly encountered biological matrices used for GC-MS based 
ante-mortem confirmatory drug analysis are whole blood or plasma/serum and urine.  
Urine is a generally preferred matrix due to the non-invasive nature of its collection, but 
it contains mostly conjugated metabolites, requiring a hydrolysis step prior to further 
analysis by gas chromatography.(85)  Blood is the biological matrix of choice in 
postmortem analysis, as it provides good quantitative information that can be compared 
to ancillary data from other sources to assist with assigning lethal drug concentrations at 
the time of death.(9)   
Extraction methods for GC analysis of designer drugs depend on the specimen 
matrix of choice, but liquid-liquid extraction (LLE) with a variety of organic solvents is 
widely used, along with SPE and mixed-mode cartridges containing hydrophobic C18 
residues and a cation-exchange resin.  Solid-phase microextraction (SPME) is not as 
widely employed, as it has not been shown to be very efficient for this class of drugs.  
Headspace analysis is also less common, due to the relatively non-volatile nature of the 
analytes, unless a derivatization step can be introduced.(86)  All phenethylamine, 
tryptamine, piperazine and cathinone derivatives contain an amine functional group.  
Such compounds tend to adsorb onto the capillary column and the glass inserts of the GC, 
causing poor peak shapes, excessive peak tailing, and poor resolution.(84)  These 
characteristics, together with the low volatility of the designer drugs, give rise to the need 
for derivatization of the analytes prior to the GC-MS analysis. 
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The amine functional group is very amenable to acylation, which is the preferred 
derivatization technique employed in designer drug analysis, although other approaches 
such as alkylation and silylation have also been successfully employed, especially with 
hydroxylated metabolites.(70)  Acetic anhydride (AA) with pyridine, trifluoroacetic 
anhydride (TFAA), and N-methyl-bis(trifluoroacetamide) (MBTFA) are the most 
convenient acylating reagents.  These introduce an acetyl or a trifluoroacetyl group onto 
the free amine moiety, resulting in more volatile analyte derivatives and a better 
separation on the GC column. The reagents are relatively inexpensive and easy to use, but 
the derivatives are prone to hydrolysis by exposure to atmospheric moisture, and some 
are only stable for a few hours.(84)  Although certain alternative reagents, such as 
pentafluoropropionic anhydride (PFPA) and heptafluorobutyric anhydride (HFBA), 
produce more stable derivatives, the reagents themselves are less volatile than AA or 
TFAA and thus require longer evaporation procedures before GC analysis.  The 
evaporation step can lead to variable co-evaporation of the designer drug derivatives, 
resulting in analyte loss and introducing error into quantitative analysis.(87) 
The capillary columns typically used in the gas chromatographic analysis employ 
non-polar (e.g., 100% dimethyl polysiloxane) or slightly polar (e.g., 5% diphenyl, 95% 
dimethyl polysiloxane) stationary phases, often made of modified polydimethylsiloxane 
polymers (MS-type columns) to reduce bleeding and improve MS analysis.  The most 
commonly used ionization source in the GC-MS analysis of designer drugs is electron 
impact ionization (EI), although many techniques also use chemical ionization in either 
positive or negative mode.  The vast majority of analyses have been performed on a 
single quadrupole mass analyzer, with a few examples available using ion trap MS.(75)  
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Analysis of amphetamines and other designer drugs by GC-MS/MS has only been done 
as a part of a screening method for different drugs of abuse in hair,(88) and no 
comprehensive study of this class of drugs using GC-triple quadrupole MS/MS has been 
published to date. 
The most popular combination of GC and a mass analyzer reported in recent 
literature is that supplied by Agilent Technologies, Inc., which couples a model 
6890/7890 GC to a model 5973 mass selective detector, or MSD.(9,67,68,69,76,77,80,89)  Limits 
of detection of the various published GC-MS methods vary depending on the specific 
compound, the matrix and the ionization source, but the numbers for blood and urine 
mostly lie in the low ppb range, with the best techniques reporting 1-50 ng/mL.  
Detection limits in hair are on the order of 100 ppb (0.1 - 0.5 ng/mg). The linear ranges of 
the various methods, when reported, are also comparable, and are on the order of 102, 
typically ranging between 10 and 2000 ppb.(84) 
2.3.2.2 LC-MS 
While GC-MS has been the gold standard for detecting drugs of abuse,(90) liquid-
chromatography coupled with mass spectrometry (LC-MS) has become more popular for 
detection and analysis of polar compounds such as amphetamines while offering higher 
sample throughput, easier sample preparation, structural elucidation, and increased 
sensitivity over GC-based methods that often require complex sample preparation and 
derivatization schemes.(41,91-92)  Additionally, LC-MS is not limited to non-polar or 
volatile compounds.(39,93-95)  Ultra-fast methods can be used when applying high-pressure 
to the chromatographic system, as is the case with UPLC, or ultra-performance liquid 
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chromatography.  More importantly, fragmentation patterns can positively identify 
compounds when MSn is used.(91) 
Liquid chromatography has been combined with diode array detection (DAD), 
single stage MS, or tandem MS for the analysis of designer drugs in biological materials.  
Diode array detection spectra may assist in the differentiation between certain isomers of 
some compounds, like mCPP.(2)  Several LC-MS based methods have been published that 
allow for the screening of different drug substance classes simultaneously.(53,96-99)  Of 
note, Wohlfarth et al. described a method for the detection of amphetamines, tryptamines, 
piperazines, and a few cathinone derivatives in human serum by LC-MS/MS, with limits 
of detection in the 1.0 to 5.0 ng/mL range.(53)  Other research has focused solely on LC-
MS analysis of single compounds and metabolites(25,40,100-102)  or on a small subset of a 
single drug class.(79,94,103-106)  Recently, cathinone derivatives have appeared on the illicit 
designer drug market and are increasing in popularity among users.  Until a couple of 
years ago, no published methods were available for comprehensive confirmatory analysis 
of these compounds.  Now, several methods have been developed with the focus on 
designer drugs, particularly the cathinone derivatives.(107-110)  However, as drug 
regulations intensify, substitution of new analogs continues, leaving laboratory methods 
one step behind the current compounds available on the market.  With the continuing 
expansion of LC-MS based methods, authors have also applied the technique to 
understanding designer drug metabolism. 
Confirmatory methods using GC rely heavily on comprehensive GC-MS libraries 
for analyte identification, which are generated using standardized instrumentation and 
ionization parameters.  However, such libraries are not as common for LC-MS based 
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drug analysis, due primarily to variations in instrumental operating parameters among 
different instruments and laboratories.  A few groups have created LC-MS databases of 
multiple designer drugs(53,81,95,111) or have published information about structural 
elucidation and fragmentation patterns of such drugs that can be helpful in identifying 
unknowns.(91,112) 
In addition to commonly employed biological matrices like blood, hair, and urine, 
several other matrices have been introduced to LC-MS techniques, including oral 
fluid,(45,61,93,113)  vitreous humor (post-mortem),(114) and exhaled breath.(44)  Depending on 
desired sample matrix available, varying extraction methods are available for LC-MS 
sample preparation; unlike GC-MS, derivatization of analytes is generally not required.  
While LLE has been utilized it requires significant amounts of solvent and is not 
amenable to automation.(51,92)  More frequently, samples for LC-MS analysis are applied 
to SPE cartridges for clean-up and pre-concentration of target compounds.  Solid phase 
extraction has several advantages, including lower cost, ease of automation, and 
increased sensitivity, especially if proper cartridge chemistry is chosen to extract 
multiple, structurally diverse analytes free from matrix effects.(48-50)  Often, reversed-
phase extraction is carried out on mixed-mode C18 sorbent beds with hydrophobic 
residues and cation-exchange resins.(115)  Liquid chromatography-mass spectrometry 
methods for designer drugs also usually employ C18 reversed-phase columns for the 
chromatographic separations along with mobile phases modified with ammonium 
formate/formic acid.(40,53,113) 
Traditionally, LC-MS methods utilize deuterated compounds as internal 
standards.(116)  When unavailable, as is often the case for new designer drugs, 
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investigators attempt to choose compounds that are similar in structure to the targeted 
analyte.  For example, Boland et al. chose 5-MeO-AMT as the internal standard for the 
analysis of AMT(25) while Pichini et al. chose MDPA as the internal standard for a variety 
of “hallucinogenic designer drugs”.(99)  When analyzing different drugs or multiple 
classes, it is important to select appropriate internal standards to represent the range of 
analytes being targeted in order to ensure accurate quantification.  The use of internal 
standards containing stable isotope labeled carbon or nitrogen may introduce unwanted 
bias or ion suppression with co-eluting peaks and is rarely used in forensic toxicological 
analysis.(117) 
Limits of detection of the various LC-MS methods depend on a variety of factors 
but are typically in the range of 0.1-5 ng/mL.(20,39,53,96,104,118,119)  Commonly, data 
acquisition is performed in MRM mode with positive electrospray ionization.(53)  Usually, 
two transitions are sufficient for qualitatively identifying a compound; however many of 
the designer drugs yield similar fragments so differentiation among positional isomers 
may be challenging.  Even with the advent of ion trap mass spectrometers, some 
compounds are still indistinguishable even at the MS6 level.(91) 
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3. CROSS-REACTIVITY OF DESIGNER DRUGS 
Copyright © 2013 John Wiley & Sons, Ltd. 
Swortwood, M. J., Hearn, W. L., DeCaprio, A. P. (2013) Cross-reactivity of designer 
drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent 
assays.  Drug Testing and Analysis DOI 10.1002/dta.1489 
3.1 Overview 
Immunoassays are designed to indicate the presence (above a certain cut-off 
concentration) of a particular class or type of substance, such as amphetamines.  For 
example, a typical toxicology laboratory may perform a drug screen with individual 
assays targeting barbiturates, benzodiazepines, cocaine, opiates, and oxycodone.  
Depending on the nature of the immunoassay (i.e., monoclonal vs. polyclonal), the 
concentration of the drugs, or the structures of the analogs, some compounds may not be 
detected.  Consequently, while these screens may perform well for known derivatives, 
they are not ideal for unclassified substances because of the likelihood of unconfirmed 
positives.  In addition, multiple classes of drugs generally cannot be detected and 
identified in a single test.(60,61)  In regulated workplace drug testing, only a few drugs are 
targeted and high specificity is a desirable characteristic for antibodies used in that field.  
However, for postmortem and human performance drug testing, broad selectivity is 
desirable. 
3.2 Introduction 
The structures of many of the stimulant-type designer drugs closely resemble 
those of amphetamine, methamphetamine, and MDMA.  Simply in terms of structural 
similarities, it is not unreasonable to expect that the antibodies used in the commercial 
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immunoassays may also recognize these drugs.(20)  However, cross-reactivity is not based 
on structural similarity alone, but also involves antibody and hapten/conjugate design.  
Consequently, it is difficult to accurately predict cross-reactivity since the latter 
parameters are typically proprietary information.  Specific immunoassays are not yet 
widely available for new designer drugs of this class, although some limited research has 
been performed to characterize the performance of pre-existing immunoassays for such 
compounds.  However, one commercial provider (Randox Laboratories) recently released 
two kits for the presumptive identification of ‘bath salts’, one targeting MDPV and 
another targeting mephedrone/methcathinone.  To date, very few investigations of the 
cross-reactivity of new designer drugs in standard immunoassays have been reported.  
Consequently, cross-reactivities still remain unknown for many drugs, particularly the 
newest compounds such as the cathinone derivatives. 
There have been several studies that have reported cross-reactivity values for 
numerous compounds with a variety of assays using spiked specimens.  Park et al. 
described the cross-reactivity of several amphetamine analogs in human urine using 
Abbott TDx (amphetamine cut-off 300 ng/mL), Vitalab Selectra (methamphetamine cut-
off 1000 ng/mL), Accusign MET (on-site test kit, methamphetamine cut-off 1000 
ng/mL), and SD Bioline MET (on-site test kit, methamphetamine cut-off 1000 ng/mL).(57)  
They demonstrated high cross-reactivities for MDA, MDMA, and MDEA for all of the 
kits, with confirmation by GC-MS.  Crooks et al. investigated an alternative matrix, oral 
fluid, in order to assess screening assays for amphetamines and methamphetamines.(59)  
Roche DAT assays (amphetamines cut-off 40 ng/mL; methamphetamines cut-off 40 
ng/mL) were evaluated with MDA, MDMA, MDEA, MBDB (N-methyl-1,3-
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benzodioxolylbutanamine), PMA (paramethoxyamphetamine), and BDB (3,4-
methylenedioxy-α-ethylphenethylamine).  Cross-reactivity was reported for PMA, MDA, 
and BDB for the amphetamine assay while MDMA, MDEA, and MBDB showed 
significant reactivity using the methamphetamine assay. 
Cody et al. used fluorescence polarization immunoassays to detect a group of 
designer drug analogs and metabolites in urine with two Abbott TDx assays 
(Amphetamine class; Amphetamine/ Methamphetamine II).(120)  High cross-reactivity 
was reported for MDA, MDMA, MDEA, and 4-hydroxymethamphetamine for both 
assays but many compounds still were either undetected or detected as positives with 
only one set of assays, indicating that a negative immunoassay result does not mean an 
amphetamine analog is not present.  Apollonio et al. also completed a study examining 
the cross-reactivities of amphetamine-type drugs using two BioQuant Direct ELISA 
assays (Amphetamine; Methamphetamine).(55)  Using a PBS (phosphate buffered saline) 
matrix, high cross-reactivity at 50 ng/mL was reported for MDA, PMA, 4-
methylthioamphetamine, and phentermine with the amphetamine assay.  They concluded 
that the assays are useful for the examination of blood, urine, and saliva at drug 
concentrations as low as 6 ng/mL without interferences from putrefactive amines.  
Recently, Kerrigan et al. published a more comprehensive evaluation of psychedelic 
phenethylamines (i.e., 2C-B, 2C-I, DOB, DOI), (121) while Nakanishi et al. reported cross-
reactivities for additional phenethylamines.(63)  However, these studies have incorporated 
relatively few designer drug compounds or synthetic cathinones, and some drugs only 
demonstrate minimal cross-reactivity, indicating that abuse of these substances may not 
be detected. 
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Several authors have also reported cross-reactivities of designer drugs when 
performing drug screens in case work for intoxications or deaths using a variety of types 
of immunoassays.  Both BZP and TFMPP have been reported to cross-react in urine at 
varying concentrations with EMIT d.a.u. (drug abuse assay) Amphetamine/ 
Methamphetamine II, Roche AbuScreen for Amphetamines, Syva EMIT II Plus for 
Amphetamines, and EMIT II Ecstasy.(122-124)  Cross-reactivity has also been reported for 
phentermine in meconium (89% at 25 ng/g using Immunalysis ELISA for amphetamine), 
AMT in urine and gastric contents (using Syva EMIT for amphetamines), and mCPP in 
urine (positive at 5000–7500 ng/mL using EMIT II Ecstasy).(25,58,124)  Others have 
reported that drugs such as DOB, 5-MeO-DiPT, 2C-T-4, and mephedrone test negative 
on screens for amphetamine, methamphetamine, or MDMA.(96,125-127)  Most recently, 
Torrance et al. reported cross-reactivity of mephedrone with a methamphetamine-based 
Immunalysis ELISA assay when investigating four fatalities.(7)  The cross-reactivities 
ranged from 1–3% in urine and blood, yet no cross-reactivity was demonstrated with the 
amphetamine assay up to 5000 ng/mL.  With regard to bath salts, cross-reactivity has 
been observed with butylone on the Microgenics CEDIA amphetamines/ecstasy 
immunoassay (128) and well as with MDPV towards the PCP (phencyclidine) assay.(129) 
Based on these data, there is a critical need in the field of forensic toxicology for 
reliable screening assays for multiple designer drugs, in addition to analytical methods 
optimized for comprehensive screening and confirmation of such drugs in a variety of 
human specimens for both ante- and post-mortem investigation.  The major goal of the 
present study was to evaluate the performance of commercially available screening 
immunoassays for detecting a wide range of designer drugs.  Since each manufacturer 
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likely uses different antibodies, the specificity cannot always be predicted or compared to 
other types of immunoassays (e.g., EMIT), different matrices (i.e., meconium, whole 
blood, oral fluid), or different manufacturers.  Regardless of the cross-reactivity that may 
occur, it is imperative that the forensic analytical toxicology community be made aware 
of the results, as screening techniques are limited for designer drugs, particularly the 
cathinone derivatives.  The present study was, in part, conducted to determine if pre-
existing immunoassays are capable of reliably detecting these compounds.  A focus was 
placed on amphetamine and methamphetamine/MDMA kits, as these types of assays are 
typically used in routine drug screens by a majority of laboratories.  Since presumptive 
methods, like ELISA, are the first line of screening methods for detecting drugs of abuse, 
it is necessary to understand how the compounds can be detected by currently available 
immunoassays, even if cross-reactivity is not expected. 
3.3 Materials and Methods 
3.3.1 Materials 
3.3.1.1 Chemicals 
The following drugs were obtained from LipoMed (Cambridge, MA, USA) as 1 
mg/mL calibrated reference standards in solvent: 2C-B, (±)-3,4,5-TMA, (±)-4-
methylethcathinone, (±)-butylone, (±)-cathinone, DMT, (±)-DOB, (±)-DOET, (±)-DOM, 
(±)-flephedrone, mCPP, (±)-MDPV, (±)-mephedrone, (±)-methcathinone, (±)-
methedrone, (±)-methylone, (±)-N-ethylamphetamine, and TFMPP.  The following drugs 
were obtained from Cerilliant (Round Rock, TX) as 1 mg/mL calibrated reference 
standards in solvent: (+)-amphetamine, (+)-methamphetamine, ketamine, 
methylphenidate, (±)-amphetamine, (±)-MDA, (±)-MDEA, (±)-MDMA, and (±)-
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methamphetamine.  The following drugs were obtained from Grace Davison Discovery 
Sciences (Deerfield, IL, USA) as 1 mg/mL calibrated reference standards in solvent: 2C-
T-4, 2C-T-7, 2C-E, 2C-I, 5-MeO-DiPT, AMT, and BZP.  An in-house standard of 
mephentermine, from powder, was available at a concentration of 1.02 mg/mL in 
methanol.  The structures for each of the assay-targeted analytes and each of the analytes 
under investigation can be found in Figure 4 and Appendix 2, respectively.  The drug 
name abbreviations can be found in Table 1.  Methanol (GC2®) was obtained from 
Honeywell Burdick & Jackson (Muskegon, MI, USA).  Dilution buffer (EIA buffer) and 
wash buffer (Wash Buffer Concentrate 10X) were obtained from Neogen Corporation 
(Lexington, KY, USA).   All other materials and solutions were included in the individual 
immunoassays listed below. 
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Figure 4: Structures of Target Compounds for ELISAs 
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3.3.1.2 ELISAs 
Sixteen immunoassay kits were obtained from four commercial manufacturers: 
Immunalysis Amphetamine Direct ELISA and Methamphetamine Direct ELISA 
(Pomona, CA); Neogen Amphetamine ELISA, Amphetamine Specific Forensic ELISA, 
Amphetamine Ultra Forensic ELISA, Benzylpiperazine Forensic ELISA, Ketamine 
Forensic ELISA, Methylphenidate Forensic ELISA, Methamphetamine/ MDMA 
Forensic ELISA, and Mephentermine Forensic ELISA (Lexington, KY, USA); Randox 
MDPV ELISA and Mephedrone/Methcathinone ELISA (Co. Antrim, UK); and OraSure 
Technologies PCP Intercept® Micro-Plate EIA, Cotinine Serum Micro-Plate EIA, 
Amphetamine-Specific Serum Micro-Plate EIA, and Methamphetamine Intercept®  
Micro-Plate EIA (Bethlehem, PA, USA).  All of the antibodies were polyclonal in nature, 
with the exception of the PCP and Amphetamine-Specific assays from OraSure.  Each kit 
consisted of 96-well microtiter plates coated with antibody for the targeted analyte, 
enzyme conjugate, TMB, and an acid stop solution.  A summary of the commercial 
immunoassays tested in this study can be found in Table 2. 
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Table 2: Commercial ELISAs 
Company Assay Targeted Analytea Type of Antibody 
Cut-Offb 
(ng/mL) 
Immunalysis 
Amphetamine Direct ELISA d-Amphetamine Polyclonal 25 
Methamphetamine Direct ELISA d-Methamphetamine Polyclonal 25 
Neogen 
Amphetamine ELISA d-Amphetamine Polyclonal 50 
Amphetamine Specific Forensic ELISA d-Amphetamine Polyclonal 50 
Amphetamine Ultra Forensic ELISA d-Amphetamine Polyclonal 50 
Benzylpiperazine Forensic ELISA Benzylpiperazine Polyclonal 25 
Ketamine Forensic ELISA Ketamine Polyclonal 50 
Methylphenidate Forensic ELISA Methylphenidate Polyclonal 10 
Methamphetamine/MDMA Forensic ELISA d-Methamphetamine Polyclonal 25 
Mephentermine Forensic ELISA Mephentermine Polyclonal 10 
Randox 
MDPV ELISA MDPV Polyclonal 10 
Mephedrone/Methcathinone ELISA Mephedrone Polyclonal 1.25 
OraSure 
PCP Intercept® Micro-Plate EIA Phencyclidine Monoclonal 20 
Cotinine Serum Micro-Plate EIA Cotinine Polyclonal 100 
Amphetamine-Specific Serum Micro-Plate EIA d-Amphetamine Monoclonal 50 
Methamphetamine Intercept® Micro-Plate EIA d-Methamphetamine Polyclonal 10 
a Assay’s targeted analyte used for controls. 
b Experimentally determined. See Materials and Methods. 
 
3.3.1.3 EMITs 
Two EMIT assays were obtained from Syva® (Siemens Healthcare Diagnostics; 
Newark, DE): EMIT® II Plus Ecstasy Assay and EMIT® II Plus Amphetamines Assay.  
The antibodies for the Ecstasy assay were polyclonal while those for the Amphetamines 
assay were monoclonal.  Each kit supplied antibodies, drug-enzyme conjugate and all 
other necessary solutions.  The EMIT® and EMIT® II Plus Ecstasy calibrators and 
controls were also purchased from Syva®.  A summary of these assays can be found in 
Table 3. 
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Table 3: Commercial EMITs 
Company Assay Type of Antibody 
Cut-Offa 
(ng/mL) 
Syva 
EMIT II Plus 
Amphetamines Monoclonal 300 
EMIT II Plus Ecstasy Polyclonal 300 
a Chosen from Manufacturer. See Materials and Methods (3.3.4.3). 
 
3.3.2 Samples 
Drug-free frozen serum, pooled from nine donors, was obtained from Utak 
Laboratories (Valencia, CA, USA) and screened negative by ELISA for amphetamine, 
benzoylecgonine, ethanol, methamphetamine, morphine, oxazepam, phencyclidine, 
secobarbital, and 11-nor-9-carboxy-THC.  This blank matrix was used for the preparation 
of controls as well as spiked samples.  After thawing, it was stored at 4°C. 
Drug-free urine was obtained from a volunteer and used for the preparation of 
spiked samples.  After collection, it was stored at 4°C. 
3.3.3 Sample preparation 
For determination of cross-reactivity by ELISA, samples of drug-free serum (0.5 
mL) were fortified with 50 µL of a methanolic spiking solution for analysis (see below).  
All calibrators, controls, and samples were subjected to a 1:4 (i.e., 5-fold) dilution with 
buffer (EIA buffer) using a Hamilton Microlab® 500 Dual Syringe Diluter (Reno, NV).  
The dilution factor chosen was recommended by the manufacturer for forensic blood 
specimens.  This helped to achieve uniformity and consistency between assays.  For 
analysis by EMIT, samples of drug-free urine (1 mL) were fortified with 100 µL of a 
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methanolic spiking solution for analysis (see section 3.3.4.2 below).  The urine samples 
were not diluted prior to analysis, per manufacturer instructions.   
3.3.4 Evaluation of cross-reactivity 
3.3.4.1 Instrumentation 
The ELISAs were performed using a DSX® Four-Plate Automated ELISA 
processing System (Dynex Technologies; Chantilly, VA, USA) operating Revelation 
version 6.15 software.  The plates were read using a 450 nm filter.  Test procedures were 
carried out according to manufacturers’ instructions listed in the package inserts, as 
summarized in Appendix 3.  All incubations were performed at ambient temperature. 
Wash buffer was diluted 10X with deionized (DI) water for use in the wash step (unless 
otherwise noted).  Conjugates that were not ‘ready-to-use’ were diluted according to the 
package inserts with the appropriate diluents provided from the manufacturer. 
EMIT was performed using a V-Twin® analyzer (Siemens).  The methods for 
qualitative analyses were downloaded from the manufacturer and carried out according to 
instructions.  Daily calibrations were performed by running the appropriate calibrators for 
a 300 ng/mL cut-off.  The calibration was validated by running negative and positive 
controls at the appropriate levels, per the kit inserts.  Once the calibration was validated, 
urine specimens were analyzed.       
3.3.4.2 Preparation of solutions 
For ‘targeted analytes’ (Figure 4), 1 mg/mL methanolic reference standards were 
diluted with methanol for a final concentration of 100,000 ng/mL working stock.  These 
were diluted further to create spiking standards at concentrations of 2,000, 1,000, 500, 
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250, 100, 50, 25, and 10 ng/mL in methanol.  For the analytes under investigation, 
‘analytes of interest’ (Appendix 2), 1 mg/mL reference standards were diluted with 
methanol (or appropriate solvent) for a final concentration of 100,000 ng/mL working 
stock.  These were diluted further to create spiking standards at concentrations of 50,000, 
25,000, 12,500, 6,250, 3,125, 1,562, 781.2, 390.6, 195.3, 97.6 ng/mL in methanol (or 
solvent). 
3.3.4.3 Establishing cut-off values 
The optimal range for cut-off values is typically provided by the kit’s 
manufacturer for enzyme-linked immunosorbent assays.  However, due to instrumental 
variation and varying matrices, it is important to determine the cut-off concentration from 
a dose response curve.  There should be a displacement between 30 and 60% of B/B0, 
where B = raw absorbance and B0 = raw absorbance of the blank matrix, in order to 
demonstrate the greatest discrimination between positives and negatives.  This level of 
displacement is consistent with the manufacturers’ kit inserts and was used for 
determining the matrix-matched serum controls for the study.  For each assay, the cut-off 
value was determined by preparing dose response curves in triplicate at decreasing 
concentrations by spiking 0.5 mL of serum with 50 µL of a methanolic spiking solution 
of the targeted analyte (10–100,000 ng/mL) to achieve concentrations in the range of 1–
10,000 ng/mL.  These samples were subjected to the dilution as previously described 
before analysis.  The absorbance values at each concentration were averaged and 
displacement was calculated.  The cut-off value with a displacement between 30 and 60% 
was chosen to be the ‘positive cut-off’ for all future experiments with that assay.  
Negative controls and positive cut-off controls, made fresh daily, were run in duplicate 
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with each assay during an experiment.  A sample whose absorbance was greater than or 
equal to 1.2 times the absorbance of the positive cut-off control was considered negative.  
A sample whose absorbance was less than or equal to the positive cut-off control was 
considered positive.  A sample whose absorbance was between that of the positive cut-off 
control and 1.2 times the absorbance of the positive cut-off controls was considered ‘+/-’ 
or indeterminate. 
For the EMIT assays, calibrators and controls were purchased from the 
manufacturer.  To calibrate the Amphetamines assay for a 300 ng/mL cut-off, EMIT® 
Calibrator/Control Level 1 was used.  To calibrate the Ecstasy assay for a 300 ng/mL cut-
off, EMIT® Ecstasy Calibrator/Control Level 2 was used.  For a negative control, 
EMIT® Calibrator/Control Level 0 was used for both assays.  For positive controls, 
EMIT® Calibrator/Control Level 5 (2,000 ng/mL) was used for Amphetamines and 
EMIT® Calibrator/Control Level 4 (1,000 ng/mL) was used for Ecstasy.  
3.3.4.4 Determining cross-reactivity 
In order to initially assess cross-reactivity by ELISA, 50 µL of each analyte of 
interest at 100,000 ng/mL was spiked into 0.5 mL of serum, in duplicate, for a final 
concentration of 10,000 ng/mL.  This concentration level was chosen based on the cross-
reactivity studies performed by the manufacturers as outlined in the package inserts.  
These samples were diluted as previously described before analysis.  The absorbance 
values at each concentration were averaged.  If a drug resulted in a ‘positive’ on the DSX 
report at this concentration when compared to the positive cut-off level, a dose response 
curve was then prepared and analyzed to calculate the cross-reactivity.  For these 
compounds, dose response curves were prepared in duplicate at decreasing 
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concentrations by spiking 0.5 mL of serum with 50 µL of a spiking solution (97.6–
100,000 ng/mL) to achieve concentrations in the range of 9.76 to 10,000 ng/mL. 
In order to calculate the percent cross-reactivity, the percent binding (calculated 
as [Asample/ Anegative]*100) was determined for each analyte at each concentration 
tested.(121)  From these values, the EC50 (half-maximal effective concentration) was also 
calculated for each targeted analyte and each analyte of interest.  The concentration of 
each analyte of interest that produced an absorbance reading closest to that of the positive 
cut-off control was also calculated.  This value is represented by the Asample/Anegative with 
a ratio closest to 1.  The positive cut-off level was then divided by the concentration of 
each analyte with the same absorbance value and expressed as a percent, representing the 
percent cross-reactivity.(121)  For terminology purposes, ‘cross-reactive’ is used for a 
compound of interest which exhibits a positive result by the DSX when compared to the 
positive cut-off control. 
In order to initially assess cross-reactivity via EMIT, 50 µL of each analyte of 
interest at 100,000 ng/mL was spiked into 0.5 mL of urine, in duplicate, for a final 
concentration of 10,000 ng/mL.  The samples were analyzed after calibration was 
validated with appropriate controls.  If a drug resulted in a “positive” on the V-Twin 
report at this concentration when compared to the cut-off level, a dose response curve 
was then prepared and analyzed to calculate cross-reactivity.  For these compounds, dose 
response curves were prepared in duplicate at decreasing concentrations by spiking 0.5 
mL of urine with 50 µL of a spiking solution (97.6 – 100,000 ng/mL) to achieve 
concentrations in the range of 9.76 – 10,000 ng/mL.  In order to calculate the percent 
cross-reactivity, the concentration of each analyte of interest that produced an absorbance 
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reading equivalent to that of the 300 ng/mL cut-off control was used (as described for the 
ELISA calculations above).    
3.4 Results and Discussion 
3.4.1 Establishing cut-off values 
For each assay, the displacement was calculated for each level of targeted analyte 
in the dose response curve.  The concentration with a displacement value from 30–60% 
was chosen as the cut-off and used as positive cut-off controls for future experiments.  A 
summary of these concentrations can be found in Table 2.  An example of a dose 
response curve used for the determination of a cut-off value for Neogen Ketamine can be 
found in Figure 5.  The values ranged from 1.25–100 ng/mL and were comparable to 
those cited in the package inserts.  While some of these levels are quite low, the assays 
are not quantitative and can only presumptively identify a class of compounds.  An 
analytical method with lower detection limits (such as LC-MS/MS) is recommended for 
confirmation or quantification of such compounds.  For the EMIT assays, there were 
several cut-off levels available among the various levels of EMIT® calibrators and 
controls.  For both the Amphetamines and Ecstasy assays, the lowest level (300 ng/mL) 
was chosen.   
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Figure 5: Ketamine Dose Response Curve 
Demonstrates displacement (%) versus concentration (ng/mL).  The ideal 
range for percent displacement is shaded.  The data point for the chosen cut-
off level is indicated by ▀.
40 
3.4.2 Determining cross-reactivity 
3.4.2.1 ELISA 
The analytes of interest which did not generate a positive result for a specific 
assay at 10,000 ng/mL were not further analyzed for that assay.  The cut-off equivalent 
concentration, percent cross-reactivity, and EC50 for these analytes were calculated using 
the value at that level.  Compounds which did indicate a positive result at 10,000 ng/mL 
were further analyzed down to concentrations as low as 10 ng/mL or until a negative 
result was produced.  The dose response curves for these analytes were constructed (% 
binding vs. analyte concentration) in order to visually examine the cross-reactivity as 
well as the EC50.  Detailed results for individual platforms are presented in Appendix 4 
for all 16 assays.  A brief summary of the findings can also be found in Table 4. 
Several assays did not exhibit cross-reactivity with any of the analytes of interest: 
Neogen Ketamine, Neogen Methylphenidate, OraSure PCP, and OraSure Cotinine.  This 
was not unexpected, due to the structural differences between the analytes targeted by the 
assay and those under investigation here.  The Neogen BZP assay demonstrated minimal 
cross-reactivity with MDEA, MDMA, and DMT at concentrations (5,000 to 10,000 
ng/mL) which most likely would not be encountered in a case.  There are other more 
sensitive assays useful for detecting MDEA and MDMA.  The cross-reactivity values for 
these compounds were less than 0.5% and are probably not significant.  As reported in 
the manufacturer package inserts, amphetamine and/or methamphetamine were without 
any cross-reactivity, consequently positives from similar compounds to the 
amphetamines would not be anticipated.  As mephentermine is structurally similar to 
methamphetamine, it was not a surprise that methamphetamine and MDMA 
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demonstrated cross-reactivity at concentrations as low as 250 and 200 ng/mL, 
respectively, with cross-reactivity values of 4% and 5%, respectively.  These 
concentrations are well within the range of those typically encountered in forensic 
specimens.  The Neogen mephentermine assay also demonstrated minimal cross-
reactivity with MDEA and ethylamphetamine, analytes that are also structurally similar.  
This cross-reactivity is also likely to be of less significance, since the positive results 
occurred at relatively high concentrations: 1,250 and 1,750 ng/mL, respectively. 
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Table 4: Summary of Cross-Reactivity Data by Assay 
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Upon investigation of the amphetamine-targeting assays, it became apparent  
these assays are quite selective.  The Immunalysis amphetamine, Neogen amphetam  
specific, and OraSure amphetamine specific assays all produced positive test results  
MDA and AMT at concentrations between 10–150 ng/mL, depending on the kit.  Th  
extensive cross-reactivity with MDA (90–250%) was expected, per the manufacture  
data.  The cross-reactivity with AMT (30–120%) was not entirely surprising, given t  
cross-reactivity reported by Boland et al. for the same compound in post-mortem uri  
and gastric contents when analyzed by EMIT amphetamine immunoassay.(25)  The o  
two assays, Neogen Amphetamine and Neogen Amphetamine Ultra, were less speci  
and demonstrated cross-reactivity with methamphetamine, MDEA, MDMA, 
ethylamphetamine, mCPP, and AMT in the range of 10–1,250 ng/mL.  The results f  
methamphetamine and MDMA were consistent with those reported in the package 
inserts. MDEA and ethylamphetamine, both structurally similar to amphetamine, we  
not included in the manufacturer’s data but the results appear reasonable given those  
MDMA.  The cross-reactivity towards AMT was also not unexpected, given the resu  
from the more specific amphetamine assays.  The most remarkable result was that fo  
mCPP, with cross-reactivity noted at concentrations of approximately 150 ng/mL fo   
of these assays, resulting in cross-reactivity values of 32%.  Without additional 
information regarding the specific antibody used in the kits (e.g., hapten and carrier  
for immunization, method of purification), it is difficult to explain this phenomenon   
However, it is corroborated by the fact that TFMPP, similar in structure to mCPP, al  
demonstrated cross-reactivity at concentrations around 2,500 ng/mL.  This result cou   
further explored by analysis with authentic specimens. 
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After examining the analytes of interest by methamphetamine-based assays, it 
was evident that the results were comparable to those using assays targeting 
amphetamine, except with regard to the cathinone derivatives.  The Immunalysis 
Methamphetamine, Neogen Methamphetamine/MDMA, and OraSure Methamphetamine 
assays displayed positive test results for MDEA, MDMA, and ethylamphetamine at low 
concentrations, with cross-reactivities between 15 and 250%.  While cross-reactivity was 
less than 2% for the cathinone derivatives using the Immunalysis or Neogen 
methamphetamine assays, with positive test results at levels as low as 1,250 ng/mL, the 
OraSure assay demonstrated greater cross-reactivity for this class of compounds.  
Positive test results for mephedrone, methcathinone, methylone, 4-MEC, flephedrone, 
butylone, and methedrone were still observed at concentrations as low as 40–450 ng/mL, 
with cross-reactivity values in the range of 2–25%.  While these findings indicate that the 
OraSure methamphetamine assay is less specific than those from Immunalysis or 
Neogen, they also demonstrate that this assay may be a viable screening tool for 
presumptively detecting bath salts in biological fluids at concentrations that can be 
encountered in forensic specimens, without necessarily targeting overdose levels.  It is 
important to note that the OraSure Methamphetamine kit is designed for screening in oral 
fluid, so it may not be commonly used by laboratories screening other matrices and may 
require additional validation. 
While the previously described assays targeted amphetamine, methamphetamine, 
or other commonly encountered drugs, the Randox assays were specifically designed to 
detect bath salts or cathinone derivatives.  The Randox MDPV assay was extremely 
selective, with only butylone demonstrating cross-reactivity at levels as low as 150 
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ng/mL.  Since the MDPV assay did not produce positive test results with other cathinone 
derivatives, it can be hypothesized that the side chain on the alpha-carbon of MDPV 
behaves similarly to the side chain on butylone.  The Randox 
Mephedrone/Methcathinone assay was less specific, since the other cathinone derivatives 
were still positive by the DSX at 150 ng/mL when compared to the positive cut-off 
control.  Alternatively, the Mephedrone/Methcathinone assay did not demonstrate cross-
reactivity towards MDPV, which might indicate that the activity is hindered by the 
nitrogen-containing ring system on MDPV.  This assay, however, did not demonstrate 
cross reactivity towards other phenethylamines.  While decomposed specimens have not 
yet been evaluated in the present study, the Randox Mephedrone/Methcathinone assay 
may be beneficial as a screening tool for targeting bath salts, as putrefactive amines may 
not interfere due to the high selectivity of these assays. 
3.4.2.2 EMIT 
The analytes of interest that did not generate a positive result for a specific assay 
at 10,000 ng/mL were not further analyzed for that kit.  The cut-off equivalent 
concentration and percent cross-reactivity were calculated using the value at that level.  
Compounds which did indicate a positive result at 10,000 ng/mL were further analyzed 
down to concentrations as low as 10 ng/mL or until a negative result was produced.  The 
dose response curves for these analytes were constructed in order to examine the cross-
reactivity.  These data are summarized in Table 5. 
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Table 5: Cross-Reactivity Data for EMITs 
 Syva Amphetamines Ecstasy 
Drug C300
a 
(ng/mL) 
Cross- 
Reactivity (%) 
C300a 
(ng/mL) 
Cross- 
Reactivity (%) 
(+)-Methamphetamine 300 100 > 10,000   < 3 
(±)-Amphetamine < 2,000 > 15 > 10,000   < 3 
2C-E > 10,000   < 3 > 10,000   < 3 
(±)-DOET > 10,000   < 3 > 10,000   < 3 
(±)-DOM > 10,000   < 3 > 10,000   < 3 
(±)-TMA > 10,000   < 3 > 10,000   < 3 
(±)-MDA < 2,000 > 15 < 2,000 > 15 
(±)-MDEA 4,000 7.5 < 2,000 > 15 
(±)-MDMA 4,000 7.5 300 100 
(±)-Ethylamphetamine < 2,000 > 15 4,000 7.5 
(±)-MDPV > 10,000   < 3 > 10,000   < 3 
(±)-Mephedrone > 10,000   < 3 > 10,000   < 3 
(±)-Cathinone > 10,000   < 3 > 10,000   < 3 
(±)-Methcathinone > 10,000   < 3 > 10,000   < 3 
(±)-Methylone > 10,000   < 3 > 10,000   < 3 
(±)-4-MEC > 10,000   < 3 > 10,000   < 3 
(±)-Flephedrone > 10,000   < 3 > 10,000   < 3 
(±)-Butylone > 10,000   < 3 4,000 7.5 
mCPP > 10,000   < 3 > 10,000   < 3 
(±)-Methedrone > 10,000   < 3 > 10,000   < 3 
5-MeO-DiPT > 10,000   < 3 > 10,000   < 3 
(±)-DOB 3,000   10 > 10,000   < 3 
2C-B > 10,000   < 3 > 10,000   < 3 
DMT > 10,000   < 3 > 10,000   < 3 
BZP > 10,000   < 3 > 10,000   < 3 
AMT 4,000 7.5 > 10,000   < 3 
2C-I > 10,000   < 3 > 10,000   < 3 
2C-T-7 > 10,000   < 3 > 10,000   < 3 
TFMPP > 10,000   < 3 > 10,000   < 3 
2C-T-4 > 10,000   < 3 > 10,000   < 3 
a Concentration of the drug that produces an absorbance reading equivalent to the 300 
ng/mL cut-off. 
Analytes demonstrating high cross-reactivity are highlighted and bolded. 
The target analytes for each assay are italicized and bolded. 
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The values for cross-reactivity for the compounds of interest were consistent with 
literature and the package inserts.  The Amphetamines assay uses d-methamphetamine as 
the cut-off control, so the results for amphetamine were to be expected.  The cross-
reactivity with MDA, MDEA, and MDMA are comparable to those in the kit insert.  
From the behavior of AMT in the serum ELISAs, the reactivity of AMT was not 
unexpected, although it was not very high.  With regard to the Ecstasy assay, the cross-
reactivities for MDA and MDEA were comparable to those stated in the package insert.  
Surprisingly, butylone exhibited some cross-reactivity down to 4,000 ng/mL, which may 
indicate the level at which antibody binding occurs.  However, the cathinone derivatives 
remained undetected by these assays at high concentrations and would not be expected to 
be identified in urine by either of these assays. 
3.5 Conclusions 
In this comprehensive study, 30 designer drug entities from the phenethylamine, 
tryptamine, and piperazine structural classes were evaluated against 16 different 
commercial ELISA kits in order to determine cross-reactivity.  Since few assays are 
currently available that target these analytes, particularly the bath salts, it was important 
to understand how they may react, especially in presumptive screens.  For the assays 
targeting amphetamine or methamphetamine, cross-reactivity towards the cathinone 
derivatives was minimal.  MDA, MDMA, ethylamphetamine, and α-methyltryptamine 
(AMT) demonstrated cross-reactivity at low concentrations, but results were consistent 
with those published by the manufacturer or as reported in the literature.  Of note, the 
cathinone derivatives demonstrated cross-reactivity at low concentrations (<150 ng/mL) 
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when analyzed against the Randox Mephedrone/Methcathinone assay.  While this assay 
seemed less selective, there was no cross-reactivity with other amphetamine-like 
compounds.  This finding suggests that the Randox assay may be useful for detecting a 
wide range of bath salts in postmortem specimens, without the usual interference from 
putrefactive amines formed during decomposition.  However, a majority of the assays 
analyzed, particularly those targeting phenethylamines, did not exhibit cross-reactivity 
with the compounds of interest, particularly the cathinone derivatives. 
An important conclusion from the present study is that current immunoassay-
based screening methods may not be ideal for presumptively identifying most designer 
drugs, including the bath salts.  Recently, there has been a trend toward the introduction 
of new immunoassays with specificity for individual designer drugs or groups of drugs, a 
development that can, at least to some extent, help address this problem.  Alternatively, 
as more laboratories move towards LC-MS/MS as an in-house analytical tool, screening 
methods for such analytes will likely gravitate towards higher specificity approaches, in 
particular high-resolution, high mass accuracy MS. 
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4. COMPREHENSIVE LC-MS METHOD 
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4.1 Overview 
Recently, the use of LC-MS for analysis of drugs of abuse has been on the rise.  
While GC-MS used to be the analytical method of choice, mass spectral library entries 
for many of the designer entities do not exist and GC-based methods are often limited to 
non-polar, volatile, and thermally stable compounds.  LC-based methods allow for 
increased sensitivity of a wide variety of compounds without the need for derivatization, 
while offering higher sample throughput, easier sample preparation, and structural 
elucidation.(41,91,92)  Ultra-fast methods, such as the one presented here, can be used when 
applying ultrahigh-pressure to the chromatographic system.  Several methods exist for the 
detection of these compounds in biological specimens but comprehensive methods 
incorporating such a high number of compounds across the three major classes are 
lacking. 
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4.2 Introduction 
In 2010, Wohlfarth et al. described a method for the detection of amphetamines, 
tryptamines, piperazines, and several cathinone derivatives in human serum by LC-
MS/MS with limits of detection in the 1.0 to 5.0 ng/mL range.(53)  However, the method 
was not fully validated and does not include some of the more popular synthetic drugs. 
Other research has focused on LC-MS analysis of a single drug class (130,131) or a smaller 
selection of analytes.(128,132)  Currently, there are few published bioanalytical methods 
available for the comprehensive confirmatory analysis of all these compounds.  The 
method presented here utilizes LC coupled to a triple quadrupole (QQQ) mass 
spectrometer for the quantification of over thirty designer drugs in serum, after sample 
processing by SPE.  LC-QQQ-MS is becoming more widely available in the forensic 
toxicology laboratory community.  In contrast, while high resolution MS, such as a 
quadrupole-time-of-flight (QTOF), is ideal for identifying designer drugs by exact mass 
analysis, the cost of instrumentation QTOF often prohibits its use in toxicology 
laboratories for method development or routine casework.  The LC-QQQ-MS method 
was fully validated and was also successfully applied to the analysis of two post-mortem 
specimens involving suspected “bath salts” use. 
4.3 Materials and Methods 
4.3.1 Chemicals 
The following drugs were obtained from LipoMed (Cambridge, MA) as 1 mg/mL 
calibrated reference standards in solvent (see Table 1 for abbreviations): 2C-B, 3,4,5-
TMA, 4-MEC, butylone, cathinone, DMT, DOB, DOET, DOM, flephedrone, mCPP, 
MDPV, mephedrone, methcathinone, methedrone, methylone, N-ethylamphetamine, and 
51 
TFMPP.  The following drugs were obtained from Cerilliant (Round Rock, TX) as 1 
mg/mL calibrated reference standards in solvent: amphetamine, MDA, MDEA, MDMA, 
and methamphetamine.  The following drugs were obtained from Grace Davison 
Discovery Sciences (Deerfield, IL) as 1 mg/mL calibrated reference standards in solvent: 
2C-T-4 2C-T-7, 2C-E, 2C-I, 5-MeO-DiPT, 5-MeO-DMT, AMT, and BZP.  The 
structures, drug classes (i.e., phenethylamines, tryptamines, and piperazines), and 
compound names can be found in Appendix 1.  Methanolic solutions of the following 
deuterated internal standards were purchased from LipoMed as 0.1 mg/mL standards: d6-
amphetamine, d5-MDMA, and d3-mephedrone.  Methanolic solutions of the following 
deuterated internal standards were purchased from Cerilliant as 0.1 mg/mL standards: d7-
BZP, d3-methylone, and d4- TFMPP.  Structures of the internal standards can be found in 
Table 6.  DBZP was purchased as a bulk powder from Sigma-Aldrich (St. Louis, MO) as 
it was not available as a calibrated reference standard. 
2-Propanol (IPA, analytical grade), acetonitrile (Optima® LC-MS grade), 
ammonium formate, hydrochloric acid (HCl, analytical grade), glacial acetic acid 
(analytical grade), and methanol (Optima® LC-MS grade) were obtained from Fisher 
Scientific (Fair Lawn, NJ).  Ammonium hydroxide (analytical grade) from Acros 
Organics (NJ), dichloromethane (analytical grade) from EMD Chemicals (Gibbstown, 
NJ), formic acid (Optima® LC-MS grade) from Fisher Scientific (Fair Lawn, NJ), and 
sodium phosphate monobasic monohydrate and dibasic heptahydrate (both analytical 
grade) from Acros (NJ) were also purchased for preparation of SPE solutions and mobile 
phases.  All water was purified using a Barnstead NanoPure Infinity filtration system 
(Dubuque, IA).  Resprep Drug Prep I cartridges (200 mg; 10 mL) for solid-phase 
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extraction were purchased from Restek (Bellefonte, PA) for manual extraction performed 
on a Supelco Visiprep-DL Disposable Liner SPE vacuum manifold. 
 
Table 6: Structures of Deuterated Internal Standards 
Internal Standard Structure 
Amphetamine-D6 
NH2D
D D D
D
D
 
MDMA-D5 
O
O CH3
NH
D D
D
D
D
 
Mephedrone-D3 
CH3
NH
O
CH3
D
D
D
 
Methylone-D3 
O
O CH3
NH
O
D
D
D
 
BZP-D7 
NH
N
D D
D
D
D
D
D
 
TFMPP-D4 NNH
F
F
F
D
D
D
D  
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4.3.2 Samples 
Pooled blank human serum recovered from six whole blood donations (three 
male, three female) was used for method development and validation and was obtained 
from Bioreclamation (Westbury, NY).  Quantitative analysis was performed on authentic 
post-mortem blood specimens that were submitted to our laboratory at Florida 
International University.  The forensic specimens contained no identifying information 
about the decedent and were merely labeled “Case 1” and “Case 2”.  All samples were 
stored at −20 °C. 
4.3.3 Sample Preparation 
Serum samples (1 mL) were diluted with 2 mL of sodium phosphate buffer (100 
mM, pH 6.0).  After addition of 20 µL of internal standards (IS) containing 1 µg/mL each 
of d6-amphetamine, d7-BZP, d5-MDMA, d3-mephedrone, d3-methylone, and d4-
TFMPP, the samples were gently vortexed and loaded onto a mixed-mode (Drug Prep I) 
SPE cartridge that was previously conditioned with 3 mL of methanol, 3 mL of water, 
and 1 mL of phosphate buffer.  After extraction, the cartridges were sequentially washed 
with 1 mL of water, 1 mL of 0.1 M acetic acid, and then 1 mL of methanol.  Vacuum was 
applied until the cartridges were dry.  Analytes were then eluted slowly using two rounds 
of 1.5 mL of elution solvent, which consisted of dichloromethane, IPA, and ammonium 
hydroxide (80:20:2 v/v/v).(53,96)  The combined eluates were acidified with 100 µL of HCl 
–IPA (1:3 v/v) before evaporation in an Eppendorf Vacufuge at 30 °C.  When dry, the 
residue was reconstituted in 50 µL of mobile phase and 5 µL of extract was injected into 
the LC-MS/MS system. 
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4.3.4 LC-QQQ Analysis 
4.3.4.1 Instrumentation 
The samples were analyzed using an Agilent 1290 Infinity Binary Pump LC 
coupled to an Agilent 6460 triple quadrupole MS/MS with Jet Streaming technology and 
electrospray ionization (ESI) using Agilent MassHunter software.  Separation occurred 
on an Agilent Zorbax Rapid Resolution HD Eclipse Plus C18 LC column (50 x 2.1 mm, 
1.8 µm particle size).  Data acquisition was performed in Dynamic MRM mode with 
positive ESI using one principal MRM transition for quantification and one additional 
transition to serve as a qualifier for each analyte. 
4.3.4.2 LC Conditions 
Chromatographic separation occurred with gradient elution at a flow rate of 0.5 
mL/min using 2 mM ammonium formate/0.1 % formic acid in water as mobile phase A 
and acetonitrile/water (90:10 v/v) with 0.1 % formic acid as mobile phase B.  The 
gradient was as follows: 5 % B up to 35 % B in 6 min as the analytical run, followed by a 
30 s ramp up to 95 % B and then a 1 min hold at 95 % B for clean-up before a 3.5-min re-
equilibration at 5 % B.  The analytical column was kept at a temperature of 40°C in a 
thermostatted column compartment during separation. 
4.3.4.3 MS parameters 
MS source parameters were as follows: gas temperature, 320 °C; gas flow 8 
L/min; nebulizer 27 psi; sheath gas heater 380 °C; sheath gas flow 12 L/min; capillary 
voltage 3,750 V; and charging voltage 500 V.  Agilent MassHunter Optimizer software 
was used to optimize the data acquisition parameters for MRM mode by automatically 
selecting the best precursor ions and associated fragmentor voltages in addition to 
55 
selecting the best fragment ions and collision energies for each transition.  Enhanced 
sensitivity was achieved with the Dynamic MRM acquisition capabilities of the Agilent 
system, which utilizes analyte retention times, detection windows (ΔtR), and a constant 
scan cycle time for precise detection of multiple analytes in a small ΔtR.  Essentially, 
Dynamic MRM will only scan for the targeted transitions within a detection window 
centered around the analyte’s retention time.  When dealing with such a large number of 
compounds, this allows for increased sensitivity as the method will only be scanning for 
the expected transitions at a given chromatographic time.  All detection windows were set 
at 0.4 min (± 0.2 min around tR).  The dynamic MRM parameters are summarized in 
Appendix 5. 
4.3.4.4 Quantification 
Agilent MassHunter Quantitative Analysis software version B.04.00 was 
employed for the quantification of the analytes.  Peak area ratios (i.e., drug vs. IS) were 
calculated and plotted against concentrations within the software.  The internal standards 
for each analyte are indicated in Appendix 5. 
4.3.4.5 Assay Validation 
The LC-MS/MS assay was fully validated according to generally accepted 
guidelines.  The experimental design for the validation experiments was based on those 
proposed by Peters et al.(133)  The parameters evaluated included selectivity, matrix 
effects, recovery, process efficiency, linearity, processed sample stability, freeze–thaw 
stability, precision, and accuracy.   
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4.3.4.6 Preparation of solutions 
Separate aqueous stock solutions were prepared during method development and 
optimization for each analyte at a concentration of 1 µg/mL from the commercially 
available calibrated reference standard (1 mg/mL for targeted compounds, 0.1 mg/mL for 
internal standards).  An aqueous spiking solution of the 32 analytes was prepared at a 
concentration of 10 µg/mL for each drug.  This stock solution was used for the 
preparation of diluted aqueous spiking solutions at concentrations of 5,000, 3,000, 2,000, 
1,000, 500, 200, 20, and 2 ng/mL each.  An aqueous spiking solution of the six internal 
standards was prepared at a concentration of 1 µg/mL each.  Separate aqueous spiking 
solutions were prepared at a concentration of 10 µg/mL and further diluted for the use in 
quality control (QC) samples.  Aliquots of each solution were frozen and stored at −20°C. 
4.3.4.7 QC Samples 
Pools of QC samples containing the above-mentioned analytes in serum were 
prepared at four different concentrations: 10 ng/mL (LOQ), 25 ng/mL (LOW), 100 
ng/mL (MED), and 250 ng/mL (HIGH).  The following volumes and concentrations were 
used to create the QC samples (volume of spiking solution, concentration of spiking 
solution, final volume): LOQ (1250 µL, 200 ng/mL, 25 mL); LOW (1750 µL, 500 
ng/mL, 35 mL); MED (1250 µL, 2000 ng/mL, 25 mL); and HIGH (1750 µL, 5000 
ng/mL, 35 mL).  Each pool was thoroughly mixed before aliquoting into 1 mL portions to 
be frozen at −20°C.  The QC samples, prepared separately from the calibrators, are 
necessary for checking daily calibration curves and ensuring quality control throughout 
the length of a batch run. 
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4.3.4.8 Selectivity 
All of the analytes and internal standards were analyzed individually at a 
concentration of 1 µg/mL with the MRM method to ensure no interfering peaks.  Then, 
samples from two different lots of blank pooled serum (each containing six donors) were 
prepared as described above to check for peaks that might interfere with the detection of 
the targeted analytes or internal standards.  A zero sample (blank matrix + IS) from each 
lot was also analyzed in order to check that the internal standards did not interfere with 
the peaks of the analytes.  A sample from each lot was also spiked with a solution 
containing all 32 analytes to check that the analytes did not interfere with the peaks of the 
internal standards.  Agilent Mass-Hunter Qualitative Analysis software version B.03.01 
was employed to analyze the resulting chromatograms. 
4.3.4.9 Matrix effects, recovery, and process efficiency 
Three sets of samples were prepared in this experiment: neat standards, spiked 
blank extracts, and extracts of spiked blanks (n=5 at each of two concentrations for a total 
of 30 samples), as recommended by Matuszewski et al.(134)  Set A consisted of adding 50 
µL of spiking solution (500 or 5,000 ng/mL each), 20 µL of internal standard solution 
(1000 ng/mL each), and 100 µL of HCl–IPA (1:3 v/v) to two 1.5-mL portions of elution 
solvent that was mixed and then evaporated to dryness at 30 °C in a vacufuge.  Then, the 
samples were reconstituted in 50 µL of mobile phase A.  Set B consisted of 1 mL samples 
of blank serum that were spiked with 70 µL of water and then extracted using the 
procedure described above.  The extracts were then spiked with 50 µL of spiking solution 
(500 or 5,000 ng/mL each) and 20 µL of IS (1,000 ng/mL each).  These were acidified, 
evaporated to dryness, and reconstituted in 50 µL of mobile phase A.  Set C consisted of 
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1 mL samples of blank serum that were spiked with 50 µL of spiking solution (500 or 
5,000 ng/mL each) and 20 µL of IS (1,000 ng/mL each) to reach nominal concentrations 
of the targeted analytes at either 25 or 250 ng/mL each in serum.  These were extracted as 
described above, acidified, evaporated to dryness, and reconstituted in 50 µL of mobile 
phase A.  For calculating matrix effect (ME), extraction efficiency/recovery (RE), and 
process efficiency (PE), absolute peak area ratios were used.  In order to estimate ME, the 
peak areas of Set B were divided by those of Set A and multiplied by 100 to determine a 
percent.  Values greater than 100 % represent ion enhancement while those less than 100 
% signify ion suppression.  For determining RE, the peak areas of Set C were divided by 
those of Set B and then multiplied by 100.  For PE, the peak areas of Set C were divided 
by those of Set A and then multiplied by 100.  Means and RSDs, expressed as 
percentages, were calculated for each parameter. 
4.3.4.10 Processed sample stability 
In order to determine the stability of processed samples under the conditions of 
the LC-MS/MS analysis, 2 mL samples of blank serum (n=8 at each of two 
concentrations for a total of 16 samples) were spiked with 100 µL of spiking solution 
(500 or 5,000 ng/mL each) and 40 µL of IS (1,000 ng/mL each) to reach nominal 
concentrations of 25 or 250 ng/mL each in serum.  The samples were extracted as 
described above, acidified, evaporated to dryness, and reconstituted in 140 µL of mobile 
phase A to ensure sufficient sample volume.  These samples were then pooled and 
aliquoted into individual autosampler vials to be placed in the autosampler.  Each sample 
was injected eight times over a course of 32 h.  The absolute peak areas were plotted 
versus time spent in autosampler.  Changes within ±15% were considered stable. 
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4.3.4.11 Linearity of calibration 
Aliquots of blank serum (1 mL) were spiked with 50 µL of the corresponding 
spiking solutions to obtain calibration samples at nominal concentrations of 500, 250, 
150, 100, 50, 25, 10, and 1 ng/mL each in serum.  Replicates (n=5) at each concentration 
were analyzed as described above.  The regression lines were calculated in Agilent 
MassHunter Quantitative Analysis software using a weighted (1/x) model in order to 
account for heteroscedasticity.  Linear regression lines were used in all but a few cases 
where slight curvature existed.  The software was also used to check precision, accuracy, 
qualifier response ratios (for analyte and for internal standard), and retention times.  The 
back-calculated concentrations were compared to their respective nominal 
concentrations.  The calibrators whose back-calculated concentrations deviated more than 
±15 % (±20 % around the LOQ) from the nominal values were excluded from the 
calculations of the daily calibration curves.  For all future validation experiments, daily 
calibration curves at the same concentrations were prepared (single measurement per 
level) and analyzed with each batch. 
4.3.4.12 Precision and accuracy 
QC samples (LOQ, LOW, MED, HIGH; n=2 at each concentration) were 
analyzed as described above on each of eight days.  The concentrations were calculated 
based on the daily calibration curves.  Accuracy was calculated in terms of bias as the 
percent deviation of the mean calculated concentration at each concentration level from 
the corresponding theoretical concentration.  Repeatability (within-day precision) and 
intermediate precision were calculated as relative standard deviation (RSD) using one-
way ANOVA (analysis of variance) with the grouping variable “day”.  Accuracy was 
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considered acceptable if bias was within ± 15 % (± 20 % around the LOQ).  Precision 
was considered acceptable if RSD was within ±15 % (±20 % around the LOQ).  A 
summary of an eight-day experiment used for determining precision, accuracy, and 
freeze-thaw stability can be found in Table 7, as adapted from Peters et al.(133) 
Table 7: Summary of Validation Experiments 
Run Cal. Levels Validation samples  Total 
  LOW MED HIGH LOQ  
  
Precision 
& 
Accuracy 
Freeze-
Thaw 
Precision 
& 
Accuracy 
Precision 
& 
Accuracy 
Freeze-
Thaw 
Precision 
& 
Accuracy 
 
1 6 2 4 control 2 2 4 control 2 22 
2 6 2  2 2  2 14 
3 6 2  2 2  2 14 
4 6 2 4 treatment 2 2 4 treatment 2 22 
5 6 2  2 2  2 14 
6 6 2  2 2  2 14 
7 6 2  2 2  2 14 
8 6 2  2 2  2 14 
Total        128 
 
4.3.4.13 Freeze-thaw stability 
For evaluation of freeze–thaw stability, QC samples (LOW and HIGH) were 
analyzed before (control samples; n=4 at each concentration) and after (stability samples; 
n=4 at each concentration) three freeze–thaw cycles.  For each cycle, the samples were 
frozen at −20 °C for 21 h, thawed, and kept at room temperature for 3 h.  The 
concentrations of the QC samples were calculated from the daily calibration curves.  
Mean concentration of stability samples was compared to mean concentration of control 
samples at each concentration.  Stability was assumed when the mean concentration of 
the stability samples was within ±10 % of the mean concentration of the control samples 
and a confidence interval of 95 % within ±20 % of the control mean concentration. 
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4.3.4.14 Limits 
In order to determine both the LOQs and LODs, aliquots of blank serum (1 mL) 
spiked with decreasing concentrations of analyte were analyzed as described above.  
Replicates (n=5) at varying concentrations in the range of 1 pg/mL to 500 ng/mL, were 
analyzed as described above.  Signal-to-noise ratio was not a technique that could be 
employed for calculating LOD or LOQ, due to the selective nature of the Dynamic MRM 
technique.  Instead, the LOD was assessed visually.  The LOQ was calculated statistically 
such that the precision and accuracy were within 20 % RSD and ±20 % bias, 
respectively.(135) 
4.3.4.15 Proof of applicability 
Blood samples from two authentic post-mortem cases were submitted for analysis 
and assayed with the described validated method. Whole heart blood was submitted as 
serum was not available from these post-mortem cases. 
4.4 Results and Discussion 
4.4.1 LC-MS/MS analysis 
The Agilent MassHunter Optimizer software was able to identify the two most 
common fragments, which were used for the quantifying and qualifying transitions, the 
collision energy, and the fragmentor voltage (summarized in Appendix 5).  The gradient 
method allowed for separation of the 32 analytes in less than a 6-min run time (Figure 6).  
The Dynamic MRM capabilities of the system allowed for increased sensitivity and 
specificity by utilizing the expected retention time of each analyte.  By determining the 
retention time, the method was able to differentiate between compounds with similar 
fragments (such as amphetamine/ methamphetamine and MDEA/MDMA) or compounds 
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with similar transitions (such as DOM/2C-E and 2C-T-4/2C-T-7).  This type of method is 
particularly useful for compounds that may co-elute or that elute close to one another 
because the individual transitions can be viewed separately without interference.  In 
addition, the deuterated internal standards were able to take any variations into account.  
Unfortunately, at the time of method development, deuterated standards were not 
available for the tryptamines.  If available in the future, a deuterated internal standard for 
this class of compounds would be recommended; alternatively, another tryptamine-like 
compound unlikely to be encountered in case samples may also be suitable. 
 
 
Figure 6: Chromatogram of Primary MRM Transitions for 32 Analytes
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4.4.2 Assay validation 
4.4.2.1 Selectivity 
Using dynamic MRM, no interfering peaks were observed when the analytes or 
internal standards were analyzed individually.  Using this approach, it is not anticipated 
that closely eluting peaks would have significant matrix effects towards other analytes 
when analyzing compound mixtures.  Compounds with similar transitions, such as DOM 
and 2C-E, could still be differentiated due to the difference in retention times.  Upon 
analysis of blank pooled serum, interfering peaks were minor and did not elute at the 
same time as any of the targeted analytes or internal standards.  In the present study, only 
deuterated compounds were chosen as internal standards, to avoid possible 
overestimation of the internal standard signal that can occur when using therapeutic drugs 
as IS.(96)  The method proved to be highly selective.  The dynamic MRM method was 
able to filter out any interferences that may have been present and the transitions chosen 
for each compound were sufficient for selectively identifying the correct compound.  
Future studies will assess and characterize the possible interferences that may result from 
xenobiotics or other drugs of abuse that may be present in authentic samples.(133,136) 
4.4.2.2 Matrix effects, recovery, and process efficiency 
The ME, RE, and PE were calculated for each analyte as described above for both 
a LOW and HIGH analyte concentration (i.e., 25 and 250 ng/mL nominal concentrations, 
respectively). The means and RSDs, expressed as percentages, are summarized in 
Appendix 6. In order to calculate ME, RE, and PE, ratios of the mean values of Sets A, B, 
and C (see above) were used. An example of the calculation for the %RSD used for ME 
is shown below, using absolute peak area means (mean) and standard deviations (SD): 
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Equation 1: Matrix Effect 
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Equation 2: Percent Relative Standard Deviation for Matrix Effect 
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The ion suppression or ion enhancement from matrix effects was generally 
acceptable (75–125 %) at both analyte concentrations.  However, DMT, 5-MeO-DMT, 
AMT, and 5-MeO-DiPT demonstrated some ion suppression (ME<75%) at 25 and 250 
ng/mL but with acceptable %RSD.  No compounds exhibited significant ion 
enhancement (ME>125 %).  While the selectivity experiment did not demonstrate any 
interferences when analyzing single compounds, future experiments will investigate ion 
suppression/ion enhancement that may occur in the analyte mixture as compared to the 
individual analytes.(136)  Recoveries were generally higher than 80%, demonstrating a 
sufficient extraction technique for most analytes.  Lower recoveries were noted for 2C-T-
4 and 2C-T-7, possibly due to different chemistries because of the presence of sulfur in 
the molecules.  Recovery values higher than 100% may represent losses that could have 
occurred in the dry down stage when Set B included spiked elutions.  The overall process 
efficiency was fairly reproducible and overall acceptable, taking into account both the 
matrix effects and recoveries.  The sample preparation approach as described is believed 
to be adequate for all specified analytes. 
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4.4.2.3 Processed sample stability 
The samples (n=8 at each 25 and 250 ng/mL nominal concentrations) were each 
injected every 4 h over 32 h.  The data for eight samples at each time point were then 
averaged (as absolute peak area) and plotted versus the time present in the autosampler.  
The changes between the final and initial values were calculated relative to the regression 
line.(137)  Values within ±15 % were considered acceptable.  The data summary can be 
found in Appendix 7, including the percent change calculated for the analyte peak area 
over the course of the run.  The % change (%Δ) as calculated by the regression lines was 
less than 15 % for all compounds at both analyte concentrations, with the exception of 
amphetamine, MDMA, TMA and the tryptamines (DMT, 5-MeO-DMT, AMT, TMA, 
and 5- MeO-DiPT).  For the latter compounds, substantially higher concentrations were 
noted at the end of the run as compared to initial.  These values may be attributed to 
sample evaporation—an effect that could potentially be mitigated by using a temperature 
controlled auto-sampler.  Amphetamine was stable for 22 h at the higher concentration 
level.  MDMA was stable for 29 h at the higher concentration level.  TMA was stable for 
only 12 h at the lower concentration level.  The tryptamines were stable for 
approximately 6 h at the lower level and approximately 21 h at the higher concentration.  
If an error were to occur during a batch analysis suspected of containing one of these 
substances, re-extraction may be necessary.  Consequently, extracts should not be re-
analyzed if left to sit for more than one day without a temperature controlled 
autosampler.  However, approximate run time for a typical experiment (which would 
equate to about 20 case samples with calibrators and QC samples) was 6 h, which is 
sufficient for the stability of all analytes. Figure 7 is an example graph for one drug 
66 
(methylone) illustrating the stability of the compound at both low and high concentrations 
over the length of the batch run. 
 
Figure 7: Processed Sample Stability for Methylone 
 
4.4.2.4 Linearity of calibration 
Agilent MassHunter Quantitative Analysis software was used to determine 
regression lines as well as to check precision, accuracy, ion response ratios, and retention 
times.  Linear regression models were weighted by a factor of 1/x to account for 
heteroscedasticity.  All R2 values were a minimum of 0.990 in this experiment.  Bias 
within ±15 % (±20 % around the LOQ) and precision within ±15%RSD (±20 % around 
the LOQ) were observed for all compounds from 10 up to 250 ng/mL.  For all further 
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experiments, the following levels were used for calibration: 10, 25, 50, 100, 150, and 250 
ng/mL.  Data for all analytes were linear between 10 and 250 ng/mL.  This calibration 
range is expected to be adequate detecting designer drugs at trace levels. Concentrations 
outside the upper limit of quantification may exhibit non-linearity; however, such 
specimens can be diluted prior to extraction in order to avoid this occurrence. 
4.4.2.5 Precision and accuracy 
The QC samples were analyzed at LOQ (10 ng/mL), LOW (25 ng/mL), MED 
(100 ng/mL), and HIGH (250 ng/mL) in duplicate on each of eight days.  Accuracy, 
repeatability, and intermediate precision were calculated for each analyte at the four 
concentrations.  The values were considered acceptable if bias was within ±15 % (±20 % 
around LOQ) and if precision was within ±15 %RSD (±20 % around LOQ).  A summary 
of these values can be found in Appendix 8.  The results for 27 analytes met all of the 
criteria for validation in terms of accuracy, repeatability, and precision as calculated for 
all four concentrations.  The results for DMT, 5-MeO-DMT, AMT, DBZP, and DOET 
demonstrated higher % bias for one or more concentration levels during the assessment 
of accuracy in QC samples, likely due to the lack of proper internal standards.  In 
addition, the stability of these compounds under auto-sampler conditions may also play a 
role in failing validation criteria.  However, in a working laboratory, values within 20 % 
RSD are generally considered acceptable.  As the data show both high and low biases for 
these analytes, it is difficult to account for the observations by any one factor alone.  
Efforts will continue to investigate potential causes of unacceptable bias for these specific 
analytes.  Consequently, the assay can only be considered semi-quantitative for these 
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compounds, and data must be evaluated based on acceptance of daily calibration curves 
and the results of the daily QC samples. 
4.4.2.6 Freeze-thaw stability 
QC samples at LOW and HIGH levels were analyzed on the first day of an 8-day 
experiment.  Additional samples were frozen and thawed with each batch before re-
analysis on the fourth day.  The concentrations were calculated from the daily calibration 
curves.  The means were compared between the “treated” and “untreated” samples at 
both concentrations and considered acceptable if the mean concentration of the treated 
samples was within ±10 % of the mean concentration of the control samples and 95 % CI 
within ±20 % of the nominal concentration.  A summary of the results can be found in 
Table 8.  All analytes were found to be stable after three freeze–thaw cycles, as 
demonstrated by the calculated differences between the treated and untreated control 
samples.  All of the changes at both the LOW and HIGH concentrations were within ±10 
% as required for validation.  The concentrations of the untreated controls were within 
±20 % of the mean concentration of the controls at a 95 % confidence interval.  This 
experiment demonstrated that samples containing these analytes can safely be analyzed 
within three freeze–thaw cycles.  However, longer-term storage stability has not been 
evaluated. 
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Table 8: Freeze-Thaw Stability of Targeted Analytes 
Compound 
LOW HIGH 
Compound 
LOW HIGH 
 (%∆)a (%∆)  (%∆)a (%∆) 
BZP 9.3 -7.4 Mephedrone 5.7 -1.2 
Cathinone -2.8 -3.1 MDEA 6 -6.8 
Methcathinone -9 -9.3 4-MEC -3.5 -9.7 
Methylone 7.6 -6.2 mCPP -5.4 1.3 
Flephedrone -6.6 -6.6 MDPV -2 -1.9 
Amphetamine 3.8 0.5 2C-B 8.5 -5.5 
MDA 2.7 -4.9 DBZP -0.9 -5.6 
Methedrone 6.6 -1.8 DOM 5.1 9.6 
Methamphetamine 2.6 -3.6 5-MeO-DiPT -0.6 -3.1 
DMT 4.6 -5.2 DOB -3.1 5.4 
MDMA 8.7 -1.1 TFMPP 6.3 1.4 
5-MeO-DMT 0.7 6.3 2C-I 2.2 -8.5 
Butylone -2.9 -6.6 2C-E 3.7 0.8 
AMT 8 -6.8 DOET 7.8 -4.7 
TMA 3.5 4.3 2C-T-4 5.2 3.4 
Ethylamphetamine 5.5 1.3 2C-T-7 6.7 7.6 
a Data expressed as % change in concentration from initial to final time point. 
 
4.4.2.7 Limits 
The LOQs and LODs were determined by spiking samples with internal standard 
and decreasing concentrations of drug and analyzing along with a calibration curve. 
LOQs were established when bias was within ±20 % and precision was within ±20 
%RSD as calculated within the Agilent MassHunter Quantitative Analysis software.  
LODs were established visually, since traditional methods such as calculating the LOD as 
three times the standard deviation of the signal-to-noise ratio is not appropriate with a 
selective method such as Dynamic MRM.  LOQs were in the range of 1–10 ng/mL, 
whereas LODs were in the range of 10–100 pg/mL.  For the validation experiments, 10 
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ng/mL was used at the LOQ level for calculations.  These LODs allow for identification 
of designer drugs at very low levels, which is extremely useful when such drugs are taken 
at sub-milligram dosages.  The LOQs accommodate very low level concentrations with 
the ability to accurately and precisely quantify the drugs that are present.  As 
demonstrated below, LOQs for the method were sufficiently sensitive to allow 
confirmation of MDPV in a case sample that was undetected by previous screens. 
4.4.2.8 Proof of applicability 
Post-mortem heart blood specimens from two forensic cases were submitted for 
analysis, as designer drugs were suspected to be present in these cases.  The first case was 
a 31 year-old black male.  The decedent died as a result of a suicidal gunshot wound to 
the head.  During routine urinalysis, MDMA was found by GC-MS in the drug screen 
and was later confirmed in urine by GC-MS.  Methylone was suspected in the GC-MS 
full scan confirmatory method but since a quantitative method was not in place the 
specimen was submitted for confirmation and quantification by the present validated LC-
MS/MS method.  The second case was a 26-year-old white male.  The decedent had been 
huffing computer aerosol and was ruled an accidental death with cause of death attributed 
to acute poly-drug toxicity, specifically citing 1,1-difluoroethane, MDMA, and 5-MeO-
DiPT.  In the initial GC-MS urine drug screen, MDA, MDMA, and 5-MeO-DiPT 
(“Foxy”) were found.  In addition, BZP, MDMA, 5-MeO-DiPT, and TFMPP were found 
in blood during a basic drug screen by GC-MS.  In both cases, the urine immunoassays 
were negative for amphetamines.  Duplicate 1-mL portions of blood from each case were 
spiked with internal standard solution and extracted as described above.  The 
concentrations of the analytes were calculated using a calibration curve and the QC 
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samples in the same run were checked for acceptable accuracy and precision.  A 
summary of the quantitative results can be found in Table 9.  Chromatograms for each 
case can be found in Figure 8 and Figure 9.   
Table 9: Summary of Quantitative Results for Case Samples 
Compound Case 1a Case 2a 
BZP ndb >250c 
Methylone 63 nd 
MDA nd 36 
MDMA 58 115 
MDPV nd 11 
5-MeO-DiPT nd >250c 
TFMPP nd 93 
a Data in ng/mL. 
b Not detected. 
c Present above highest calibration level 
The concentrations of BZP and 5-MeO-DiPT were greater than the upper limit of 
quantification and would need to be re-analyzed after performing a sample dilution in 
order to ensure that they would be within the linear range.  Insufficient sample volume 
was available for dilution of these specimens in the present study.  Future experiments 
assessing the validity of this additional step would need to be performed in order to 
determine precision and accuracy of diluted samples.  In addition, these values were 
extremely high relative to some other reported cases and were probably contributing 
factors to the decedent’s death.(2,6)  It is important to note that the calibration curve for 5-
MeO-DiPT and the daily QC samples were acceptable on the day that these samples were 
analyzed.  It is not uncommon to see the combination of BZP with TFMPP, as was noted 
for Case 2.(2,138)  The concentrations of the other compounds detected were comparable to 
those that were initially quantified by the submitting laboratory.  Significantly, MDPV 
was found in Case 2 by the present method but had been missed in the initial GC-MS 
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screens.  The presence of “bath salts” was confirmed for both cases (methylone and 
MDPV, respectively) and establishes that these compounds are present in the local 
community.  As the validated serum extraction procedure was adapted to whole blood in 
these cases, additional validation studies would be investigated in the future for this type 
of biological specimen, particularly with regard to matrix effects and recovery. 
 
Figure 8: Chromatogram of Case 1 (counts vs. acquisition time) 
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Figure 9: Chromatogram of Case 2 (counts vs. acquisition time) 
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4.5 Conclusions 
A LC-QQQ-MS/MS assay developed for the determination of 32 important 
designer drug entities in serum was fully validated for 27 analytes as per international 
guidelines.  The remaining analytes, all from the tryptamine group, did not completely 
meet the criteria for precision and accuracy.  Consequently, the method can only be 
considered semi-quantitative with regard to these compounds, necessitating the use of 
daily calibration curves and QC samples for acceptability.  The extraction was 
successfully applied to serum specimens with high recovery and minimal matrix effects.  
In addition, the method was also effectively utilized for the analysis of two forensic 
whole blood specimens suspected of involving bath salts.  This comprehensive technique 
has demonstrated value as a validated analytical assay with applicability to forensic 
toxicological casework.  It is currently being expanded to encompass many additional 
designer drugs that have been introduced to the illicit market since the conclusion of this 
project. 
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5. ANALYSIS OF FORENSIC CASE SAMPLES 
5.1 Overview 
In forensic science, one of the most important tasks in regard to method 
development is the application.  Specimens were analyzed by both immunoassays and the 
confirmatory LC-MS method that was previously validated.  The dual-analysis allowed 
for true comparison of the two techniques (immunoassay and LC-MS) as well as 
assessment of the comprehensive LC-MS method when applied towards forensic case 
samples. 
5.2 Introduction 
Obtaining biological case samples from forensic laboratories is very difficult due 
to pending investigations and following proper chain-of-custody.  In an attempt to 
compare the immunoassay and confirmatory techniques previously described in Chapters 
3 and 4, specimens were prepared in a blind study by the research advisor at varying 
concentrations and in various combinations in order to test the screening capabilities of 
the two methods in an unbiased manner and confirm any false positives or false negatives 
that might occur.  In addition, several authentic forensic specimens were received from 
Palm Beach County Sheriff’s Office Toxicology Unit.  
5.3 Materials and Methods 
5.3.1 Materials 
5.3.1.1 Chemicals 
The following drugs were obtained from LipoMed (Cambridge, MA) as 1 mg/mL 
calibrated reference standards in solvent: 2C-B, (±)-3,4,5-TMA, (±)-4-
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methylethcathinone, (±)-butylone, (±)-cathinone, DMT, (±)-DOB, (±)-DOET, (±)-DOM, 
(±)-flephedrone, mCPP, (±)-MDPV, (±)-mephedrone, (±)-methcathinone, (±)-
methedrone, (±)-methylone, (±)-N-ethylamphetamine, and TFMPP.  The following drugs 
were obtained from Cerilliant (Round Rock, TX) as 1 mg/mL calibrated reference 
standards in solvent: d-amphetamine, d-methamphetamine, ketamine, methylphenidate, 
(±)-amphetamine, (±)-MDA, (±)-MDEA, (±)-MDMA, and (±)-methamphetamine.  The 
following drugs were obtained from Grace Davison Discovery Sciences (Deerfield, IL) as 
1 mg/mL calibrated reference standards in solvent: 2C-T-4, 2C-T-7, 2C-E, 2C-I, 5-MeO-
DiPT, AMT, and BZP.  An in-house standard of mephentermine, from powder, was 
available at a concentration of 1.02 mg/mL in methanol.  The structures for each of the 
assay-targeted analytes and each of the analytes under investigation can be found in 
Figure 4 and Appendix 2, respectively.  Methanol (GC2®) was obtained from Honeywell 
Burdick & Jackson (Muskegon, MI).  Dilution buffer (EIA buffer) and wash buffer 
(Wash Buffer Concentrate 10X) were obtained from Neogen Corporation (Lexington, 
KY).  All other solutions and materials were included in the individual immunoassays 
listed below. 
Iso-Propanol (IPA, analytical grade), acetonitrile (Optima® LC-MS grade), 
ammonium formate, hydrochloric acid (HCl, analytical grade), glacial acetic acid 
(analytical grade), water (Optima® LC-MS grade), and methanol (Optima® LC-MS 
grade) were obtained from Fisher Scientific (Fair Lawn, NJ).  Ammonium hydroxide 
(analytical grade) from Acros Organics (NJ), dichloromethane (analytical grade) from 
EMD Chemicals (Gibbstown, NJ), formic acid (Optima® LC-MS grade) from Fisher 
Scientific (Fair Lawn, NJ), and sodium phosphate monobasic monohydrate and dibasic 
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heptahydrate (both analytical grade) from Acros (NJ) were also purchased for preparation 
of SPE solutions and mobile phases. Clean Screen® Extraction Columns (CSDAU, 200 
mg; 10 mL) for solid-phase extraction were purchased from United Chem (Bristol, PA) 
for manual extraction performed on a positive pressure manifold from United Chem 
(Bristol, PA).  
5.3.1.2 ELISAs 
Sixteen immunoassay kits were obtained from four commercial manufacturers: 
Immunalysis Amphetamine Direct ELISA and Methamphetamine Direct ELISA 
(Pomona, CA); Neogen Amphetamine ELISA, Amphetamine Specific Forensic ELISA, 
Amphetamine Ultra Forensic ELISA, Benzylpiperazine Forensic ELISA, Ketamine 
Forensic ELISA, Methylphenidate Forensic ELISA, Methamphetamine/ MDMA 
Forensic ELISA, and Mephentermine Forensic ELISA (Lexington, KY, USA); Randox 
MDPV ELISA and Mephedrone/Methcathinone ELISA (Co. Antrim, UK); and OraSure 
Technologies PCP Intercept® Micro-Plate EIA, Cotinine Serum Micro-Plate EIA, 
Amphetamine-Specific Serum Micro-Plate EIA, and Methamphetamine Intercept®  
Micro-Plate EIA (Bethlehem, PA, USA).  All of the antibodies were polyclonal in nature, 
with the exception of the PCP and Amphetamine-Specific assays from OraSure.  Each kit 
consisted of 96-well microtiter plates coated with antibody for the targeted analyte, 
enzyme conjugate (3,3’,5,5’-tetramethylbenzidine or TMB substrate solution), and an 
acid stop solution.  A summary of the commercial immunoassays tested in the current 
study can be found in Table 2. 
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5.3.2 Samples 
Drug-free frozen serum, pooled from nine donors, was obtained from Utak 
Laboratories (Valencia, CA, USA) and screened negative by ELISA for amphetamine, 
benzoylecgonine, ethanol, methamphetamine, morphine, oxazepam, phencyclidine, 
secobarbital, and 11-nor-9-carboxy-THC.  The blank serum was used for the preparation 
of matrix-matched controls.  After thawing, it was stored at 4°C.  For the preparation of 
whole blood controls, blank donor blood was obtained from Biological Specialty 
Corporation (Colmar, PA) as a single unit.  It had been screened negative by ELISA for 
benzoylecgonine, secobarbital, carisoprodol, oxazepam, morphine, and oxycodone.  It 
was also stored at 4°C. 
For comparison of results using ELISA and LC-MS screening assays, 22 five mL 
serum samples were prepared and analyzed in a blind manner (i.e., without analyst 
knowledge of drug identity or concentration).  For the blind study, drug-free serum was 
spiked by the research advisor with known amounts of drug reference standards in 
methanolic solution.  Samples were prepared that included single or mixtures of drugs 
and were prepared at a range of concentrations simulating those expected to be 
encountered in authentic specimens.  The samples were given a random ID number (1- 
22) and frozen at -20°C until analysis by ELISA and LC-MS.  Blind spiked sample 
compositions are summarized in Table 10.  In regard to the two case samples analyzed 
during LC-MS method validation (Chapter 4), there was insufficient volume for 
additional analysis in this study.   
In addition to the spiked specimens, five authentic specimens were received from 
Palm Beach County Sheriff’s Office (PBSO) Toxicology Unit.  The whole blood 
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specimens were stored in 10 mL grey top (fluoride and oxalate) vacutainers for 1-2 years 
mostly at room temperature but never opened.  The samples were supplied with no 
personal identifying information; each was assigned an ID number (7-001, 11-001, 11-
002, 12-001, and 12-002) for internal tracking purposes only.  It was indicated by PBSO 
that the samples were “positive for drugs,” but no cathinone derivatives had been 
previously detected by their screening techniques.  Upon receipt at FIU, the specimens 
were stored at 4°C. 
Table 10: Composition of Serum Samples Spiked in Blind Study 
ID Drug(s) nominal concentration (ng/mL) 
1 methylone 20 
2 methylone 20 
3 ethylamphetamine 100 
4 ethylamphetamine 100 
5 no spike 0 
6 methamphetamine + methedrone 100 + 100 
7 methamphetamine + methylone 100 + 100 
8 methamphetamine + 2C-I 100 + 100 
9 methamphetamine + MDMA 120 + 120 
10 methylone + flephedrone 120 + 120 
11 amphetamine + mCPP 100 + 100 
12 methylone + 5-MeO-DiPT 100 + 100 
13 2C-I + 2C-T-7 100 + 100 
14 MDPV + mephedrone 100 + 100 
15 AMT + butylone + ethylamphetamine 100 + 100 + 100 
16 no spike 0 
17 2C-I 20 
18 2C-I 60 
19 2C-I 200 
20 flephedrone 20 
21 flephedrone 60 
22 flephedrone 200 
 
 
80 
5.3.3 Sample preparation 
For immunoassay screening by ELISA, all calibrators, controls, and samples were 
subjected to a 1:4 (i.e., five-fold) dilution with buffer (EIA buffer) using a Hamilton 
Microlab® 500 Dual Syringe Diluter (Reno, NV).  The dilution factor chosen was 
recommended by the manufacturer for forensic blood specimens.   
For analysis by LC-MS, a solid phase extraction was performed to clean up the 
sample and isolate the drug.  Serum samples (1 mL) were diluted with 2 mL of phosphate 
buffer (0.1 M, pH 6.0).  The samples were gently vortexed and loaded onto a Clean 
Screen® SPE cartridge previously conditioned with 3 mL of methanol, 3 mL of water, 
and 1 mL of phosphate buffer.  After extraction, the cartridges were sequentially washed 
with 1 mL of water, 1 mL of 0.1 M acetic acid, and then 1 mL of methanol.  Pressure was 
applied until the cartridges were dry.  Analytes were eluted slowly with 3 mL of elution 
solvent, which consisted of dichloromethane, IPA, and ammonium hydroxide (80:20:2 
v/v/v).  The eluates were acidified with 100 µL of 1% HCl in methanol before 
evaporation under nitrogen at 40°C in a TurboVap® LV by Caliper Life Sciences 
(Hopkinton, MA).  When dry, the residue was reconstituted in 50 µL of mobile phase A 
(2mM ammonium formate, 0.1% formic acid in water) and 5 µL were injected into the 
LC-MS system.      
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5.3.4 Instrumentation 
5.3.4.1 ELISA 
Enzyme-linked immunosorbent assays were performed using a DSX® Four-Plate 
Automated ELISA processing System (Dynex Technologies; Chantilly, VA) operating 
Revelation version 6.15 software.  The plates were read using a 450 nm filter.  Test 
procedures were carried out according to manufacturers’ instructions listed in the 
package inserts, as summarized in Appendix 3.  All incubations were performed at 
ambient temperature.  Wash buffer was diluted 10X with deionized (DI) water for use in 
the wash step (unless otherwise noted).  Conjugates that were not “ready-to-use” were 
diluted according to the package inserts with the appropriate diluents provided from the 
manufacturer. 
5.3.4.2 LC-MS 
The LC-MS analysis was performed using two systems.  Qualitative screening by 
LC-QQQ-MS employed an Agilent 1290 Infinity Binary Pump LC coupled to an Agilent 
6460 triple quadrupole MS/MS with Jet Streaming Technology and electrospray 
ionization (ESI) using Agilent MassHunter software.  Separation occurred on an Agilent 
Zorbax Rapid Resolution HD Eclipse Plus C18 LC column (50 x 2.1 mm, 1.8 µm particle 
size).  Data acquisition was performed in Dynamic MRM mode with positive ESI using 
one principal MRM transition for quantification and one additional transition to serve as 
a qualifier for each analyte.  Samples were also analyzed by high-resolution MS for 
confirmation and library matching.  For this purpose, an Agilent 1290 Infinity Binary 
Pump LC coupled to an Agilent 6530 quadrupole time-of-flight (QTOF) MS was utilized.  
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The same LC column as described above was used for separation.  Data acquisition was 
performed in full-scan mode with positive ESI. 
Chromatographic separation occurred with gradient elution at a flow rate of 0.5 
mL/min using 2 mM ammonium formate/0.1% formic acid in water as mobile phase A 
and acetonitrile/water (90:10 v/v) with 0.1% formic acid as mobile phase B.  The gradient 
was as follows: 5% B up to 35% B in 6 minutes as the analytical run, followed by a 30 s 
ramp up to 95% B and then a 1 minute hold for clean-up before a 3.5 minute re-
equilibration at 5% B.  The analytical column was kept at a temperature of 40°C in a 
thermostatted column compartment during separation.   
Source parameters for QQQ-MS were as follows: gas temperature 320°C; gas 
flow 8 L/min; nebulizer 27 psi; sheath gas heater 380°C; sheath gas flow 12 L/min; 
capillary voltage 3,750 V; and charging voltage 500 V.  The method parameters are 
summarized in Appendix 5.  Data were acquired in Dynamic MRM mode with two 
transitions per analyte and compounds were identified using Agilent MassHunter 
Qualitative Analysis software.  Compounds were identified qualitatively by examining 
retention time and ion ratios for both transitions.  Compounds were quantified against a 
calibration curve using Agilent MassHunter Quantitative Analysis software.     
Source parameters for QTOF-MS analysis were as follows: gas temperature 
320°C; gas flow 8 L/min; nebulizer 27 psi; sheath gas heater 380°C; sheath gas flow 12 
L/min; capillary voltage 3,750 V; nozzle voltage 500 V; fragmentor 125; skimmer 65; 
octapole RF peak 750.  Agilent MassHunter Qualitative Analysis software was employed 
for the identification of analytes.  An in-house library with exact mass data was used for 
confirmation of the analytes.  Retention time, as known from the QQQ method, was also 
83 
considered when making matches.  A software score of 90 or greater was considered a 
match if there was also minimal difference between the actual and expected mass. 
5.3.5 QC Samples 
 When analyzing the spiked samples by ELISA, fresh negative and positive cut-off 
controls (Chapter 3) were prepared and analyzed as described above.  When analyzing 
the spiked samples by LC-MS, calibrators and QC samples (Chapter 4) were prepared 
and analyzed as described above.  
5.4 Results and Discussion 
The 22 spiked blinded serum samples were thawed and screened by all 16 ELISA 
assays as listed in Table 2.  The samples were diluted as described above and analyzed 
against fresh positive and negative serum controls.  The results are shown in Appendix 9.  
All of the samples screened positive for cotinine using the OraSure assay.  The blank 
serum used for the preparation of the controls was different than the lot of blank serum 
used to prepare the blind spiked specimens and therefore likely contained higher levels of 
the nicotine metabolite.  Since this assay did not exhibit any cross-reactivity towards the 
analytes of interest during the initial stages of this study, it was determined that the 
positive reactions were from the matrix alone and not from any of the drugs that may 
have been added.  Several samples gave indeterminate results, as indicated by “±” in the 
table. 
Spiked samples were extracted by SPE as described under Materials and Methods.  
The results obtained by LC-QQQ-MS confirmed many of the “false-positives” obtained 
during the ELISA screening of these samples.  For example, the ELISA assays targeting 
methamphetamine gave positive results for samples that did not contain 
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methamphetamine, (i.e., samples 3, 4, 11, 14, and 15).  The assay targeting amphetamine 
gave positives for samples that did not contain amphetamine (i.e., samples 3, 4, 6, 7, 8, 9, 
and 15).  The MDPV assay successfully detected the analyte in sample 14 but gave 
indeterminate results for samples 3, 4, 8, and 15, which did not contain this compound.  
The Mephedrone/Methcathinone assay was able to successfully detect cathinone 
derivatives in 10 out of the 11 samples which contained such analytes.  The other case, 
sample 20, was determined to contain flephedrone at a low concentration that was 
otherwise undetected by the immunoassays.  Samples such as 13, 17, 18, and 19, which 
were assumed negative by immunoassay, were determined to contain 2C compounds 
when analyzed by LC-QQQ-MS.     
The blind spiked samples were also analyzed by LC-QTOF-MS to confirm the 
results of the ELISA and LC-QQQ-MS analyses by means of high-resolution mass 
spectral library matching.  The samples were analyzed in full-scan mode and compared to 
a full-scan library, while also considering retention time in identification of the analyte.  
The results are summarized in Table 11.  An example of an extracted ion chromatogram 
and a library match for sample 1 can be found in Figure 10.  Methamphetamine, 
amphetamine, and MDMA were not included in the mass spectral library and therefore 
could not be confirmed in samples 6, 7, 8, 9, and 11.  There were no library matches 
found for samples 5 and 16, an expected result since these were negative samples.  With 
the exceptions noted above, all of the compounds were successfully identified by QTOF-
MS with high confidence, based on the high-resolution parent mass data obtained.  With 
the exceptions of methedrone, butylone, and AMT, all of the compounds identified by the 
library had ID scores of at least 90 as provided by the Agilent MassHunter software. 
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Figure 10: Extracted Ion Chromatogram and Library Match for Sample 1 
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Table 11: LC-QTOF Data for Blind Spiked Samples 
Sample Match Observed Mass 
Target 
Mass 
Difference 
(ppm) Score 
Sample 
01 Methylone 207.0886 207.0895 -4.3 94.99 
Sample 
02 Methylone 207.0889 207.0895 -2.9 94.45 
Sample 
03 Ethylamphetamine 163.1352 163.1361 -5.48 94.77 
Sample 
04 Ethylamphetamine 163.1354 163.1361 -4.58 96.91 
Sample 
05 None     
Sample 
06 Methedrone 193.1086 193.1103 -8.54 79.17 
Sample 
07 Methylone 207.0883 207.0895 -5.96 91.92 
Sample 
08 2C-I 307.006 307.0069 -2.96 97.08 
Sample 
09 None     
Sample 
10 
Methylone 207.0892 207.0895 -1.47 96.22 
Flephedrone 181.0899 181.0903 -1.88 99.24 
Sample 
11 mCPP 196.0759 196.0767 -4.04 95.37 
Sample 
12 
Methylone 207.0883 207.0895 -5.93 91.66 
5-MeO-DiPT 274.2034 274.2045 -4.18 93.9 
Sample 
13 
2C-I 307.0057 307.0069 -4.05 94.85 
2C-T-7 255.128 255.1293 -5.16 92.26 
Sample 
14 
Mephedrone 177.1146 177.1154 -4.23 96.86 
MDPV 275.1508 275.1521 -4.75 93.07 
Sample 
15 
AMT 174.1145 174.1157 -6.62 80.41 
Butylone 221.1037 221.1052 -6.95 88.85 
Ethylamphetamine 163.1353 163.1361 -5.07 94.3 
Sample 
16 None     
Sample 
17 2C-I 307.0078 307.0069 2.78 97.21 
Sample 
18 2C-I 307.0057 307.0069 -3.86 95.05 
Sample 
19 2C-I 307.0059 307.0069 -3.35 96.3 
Sample 
20 Flephedrone 181.0899 181.0903 -2.41 98.28 
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Sample Match Observed Mass 
Target 
Mass 
Difference 
(ppm) Score 
Sample 
21 Flephedrone 181.0892 181.0903 -6.23 92.78 
Sample 
22 Flephedrone 181.0893 181.0903 -5.7 94.01 
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The five authentic blood samples obtained from PBSO were screened by all 16 
ELISA assays as listed in Table 2.  The samples were diluted as described above and 
analyzed against fresh positive and negative serum controls as well as whole blood 
controls (to ensure appropriate displacement with the different matrix).  The results are 
shown in Appendix 10.  None of the samples tested positive in any of the 16 assays, 
except for 11-002, 12-001, and 12-002, which were positive for cotinine.  Since this assay 
did not exhibit any cross-reactivity towards the analytes of interest during the initial 
stages of this study, it was determined that the positive reactions were from nicotine use.   
The PBSO samples were also analyzed by LC-QTOF-MS to confirm the results of 
the ELISA by means of high-resolution mass spectral library and/or database matching.  
A library search provides matching based on spectral data while a database search 
provides matching based on mass.  The samples were analyzed in full-scan mode and 
compared to an in-house designer drug library and database as well as a forensic 
toxicology library and database from Agilent Technologies.  The results are summarized 
in Table 12.  The positive cotinine ELISA results were confirmed for 11-002, 12-001, 
and 12-002 by the identification of cotinine and/or 3-hydroxycotinine, indicative of 
nicotine use.  None of the targeted designer drug analytes of this research were identified 
by the in-house designer drug library or database.  The negative LC-QTOF findings for 
the designer drugs are consistent with the negative ELISA results for the amphetamine-
type compounds.  However, other drugs and their metabolites were detected as 
summarized in the table.  These results remain presumptive as these analytes were not a 
part of this study and certified reference standards were not available to confirm retention 
time or the library results.       
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Table 12: LC-QTOF Data for PBSO Samples 
Sample Library Matches 
7-001 diphenhydramine, methadone, EDDP (methadone metabolite) 
11-001 tramadol 
11-002 Benzoylecgonine, morphine, dihydromorphine, cyclobenzaprine, 3-hydroxycotinine 
12-001 benzoylecgonine, 3-hydroxycotinine 
12-002 3-hydroxycotinine, cotinine, tramadol, citalopram, norcitalopram 
 
5.5 Conclusions 
The comparison of immunoassays to the LC-MS methods demonstrated that false 
positives and false negatives can occur and require confirmatory techniques, such as LC-
QQQ or LC-QTOF, to accurately identify drugs that may be present in a biological 
sample.  The immunoassays were able to detect some of the compounds present, but gave 
some indeterminate or negative results in cases that were not truly negative.  The two LC-
MS methods were able to confirm and identify, with MRM and/or exact mass data, the 
identities of the compounds that were present, even at low levels.  The current study 
reiterates the need for laboratories to gravitate towards LC-based methods, as screening 
techniques such as immunoassays are not sufficient for detecting most of these designer 
drugs.  As the structures of these compounds constantly evolve, screening techniques will 
require more sensitive, selective methods, such as LC-QTOF, in order to positively 
identify this type of analyte, since designing antibodies for immunoassays will be too 
lengthy of a process.    
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6. SUMMARY AND PROSPECT 
Current immunoassay-based screening methods are not ideal for presumptively 
identifying most designer drugs, including the “bath salts”.  Recently, there has been a 
trend toward the introduction of new immunoassays with specificity for individual 
designer drugs or groups of drugs, a development that can, at least to some extent, help 
address this problem.  Alternatively, as more laboratories move towards LC-MS/MS as 
an in-house analytical tool, screening methods for such analytes will likely gravitate 
towards higher specificity approaches, in particular high-resolution, high mass accuracy 
MS. 
The expected results of this study were obtained, as it was hypothesized that 
commercial immunoassays would not detect the cathinone derivatives and other designer 
drugs outside the realm of the traditional phenethylamines, such as amphetamine, 
methamphetamine, and MDMA.  The lack of cross-reactivity demonstrates that forensic 
toxicology laboratories will not be able to solely rely on immunoassays for screening 
procedures.  More advanced analytical techniques, such as LC-MS, are required for the 
identification of these compounds, as demonstrated by the LC-QQQ and LC-QTOF 
analyses.  Laboratories should keep cross-reactivity, or the lack thereof, in mind when 
performing routine screens so that these types of compounds are not overlooked.  With 
the exception of the Randox kits, few immunoassays have been developed to target these 
analytes.  While oral fluid may not be a commonly analyzed matrix, the results obtained 
for the cross-reactivity of the cathinone derivatives in serum by the OraSure 
Methamphetamine assay indicate its possible use for detecting such compounds, but 
would require extensive validation for this matrix and would not be applicable to every 
91 
cathinone derivative as MDPV was not cross-reactive.  In addition, this study only 
incorporates thirty designer drugs, of which only eight were cathinone derivatives.  Many 
more compounds exist in the drug market and continue to be synthesized such that this 
research cannot be considered comprehensive or complete.  Toxicology labs should and 
will continue to move towards LC-MS or other advanced techniques for the detection of 
these compounds in routine screenings of biological specimens.     
For future studies, additional commercial immunoassays could be investigated to 
determine the cross-reactivity for those thirty compounds of interest.  As the designer 
drugs in the market become more diversified, additional analytes may need to be 
examined for cross-reactivity.  While computational modeling can help to predict cross-
reactivity, actual experiments will be necessary to indicate the real-life nature of forensic 
specimens.  Since cathinone derivatives have only been made popular over the past few 
years, it is difficult to forecast the long-term trends of abuse for these drugs.  If persistent, 
antibodies may need to be developed to create more commercial immunoassays like the 
one already released by Randox, so that high-throughput, automated screens can be used 
to presumptively identify these compounds.  However, since there are so many designer 
drugs with similar masses and structures, high-resolution mass spectrometry will be the 
best technique for identifying these compounds and will likely be the future focus of 
qualitative and quantitative methods.  As standards become available, updating the 
confirmatory LC-MS method presented in this research would allow for more broad-
based screening.  Further incorporation of LC-QTOF would allow for exact-mass 
capabilities and structural elucidation.  Data mining could also be performed using high 
resolution mass spectral data as standards become available and libraries are updated. 
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APPENDICES 
Appendix 1: Designer Drugs by Class and Sub-class 
Class Basic Structure Substituents Name/Abbreviation 
PHENETHYLAMINES 
2,5-dimethoxy-amphetamines R1
NH
CH3
O
O
CH3
CH3
R2
 
R1 = Br, R2 = H 
R1 = C2H5, R2 = H 
R1 = CH3, R2 = H 
R1 = O-CH3, R2 = H 
DOB 
DOET 
DOM 
TMA 
PHENETHYLAMINES 
2Cs R
NH2O
O
CH3
CH3  
R = Br 
R = C2H5 
R = I 
R = S-CH(CH3)2 
R = S-C3H7 
2C-B 
2C-E 
2C-I 
2C-T-4 
2C-T-7 
PHENETHYLAMIMES 
3,4-methylene- 
dioxyamphetamines 
O
O
CH3
NH
R
 
R = H 
R = C2H5 
R = CH3 
MDA 
MDEA 
MDMA 
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Class Basic Structure Substituents Name/Abbreviation 
PHENETHYLAMINES 
Amphetamines CH3
NH
R
 
R = H 
R = CH3 
R = C2H5 
Amphetamine 
Methamphetamine 
Ethylamphetamine 
PHENETHYLAMINES 
Pyrrolidinophenones 
R1
R2
R3
N
O
 
R1 = R2 = O-CH2-O, R3 = C3H7     MDPV 
PHENETHYLAMINES 
β-keto-amphetamines 
 
R
1
NH
O
R
2
 
 
 
O
O
R1
NH
R2
O
 
R1 = R2 = CH3 
R1 = R2 = H 
R1 = H, R2 = CH3 
R1 = O-CH3, R2 = CH3 
R1 = CH3, R2 = C2H5 
R1 = F, R2 = CH3 
 
R1 = R2 = CH3 
R1 = C2H5, R2 = CH3 
Mephedrone 
Cathinone 
Methcathinone 
Methedrone 
4-Methylethcathinone 
Flephedrone 
 
Methylone 
Butylone 
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Class Basic Structure Substituents Name/Abbreviation 
PIPERAZINES 
Benzylpiperazines N
N
R  
R = H 
R = CH2-C6H5 
BZP 
DBZP 
PIPERAZINES 
Phenylpiperazines 
R
NNH
 
R = Cl 
R = CF3 
mCPP 
TFMPP 
TRYPTAMINES R2R1
N
H
N
R
3
R
4
 
R1 = R3 = R4 = H, R2 = CH3 
R1 = R2 = H, R3 = R4 = CH3 
R1 = O-CH3, R2 = H, R3 = R4 = CH3 
R1 = O-CH3, R2 = H, R3 = R4 = CH(CH3)2 
AMT 
DMT 
5-MeO-DMT 
5-MeO-DiPT 
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Appendix 2: Designer Drugs of Interest by Structure 
Phenethylamines 
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Piperazines and Tryptamines 
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Appendix 3: Test Procedures for ELISA Analysis 
Manufacturer Assay 
Sample 
Volume 
(µL) 
Conjugate 
Volume (µL) 
Incubation 
Time (min) 
No. of 
Wash 
Cycles 
Wash 
Volume 
(µL) 
Wash 
Solution 
Substrate 
Volume (µL) 
Incubation 
Time (min) 
Stop Reagent 
Volume (µL) 
Immunalysis 
Amphetamine 10 100 60 6 350 DI water 100 30 100 
Methamphetamine 10 100 60 6 350 DI water 100 30 100 
Neogen  
Amphetamine 20 180 45 5 300 Wash buffer 150 30 50 
Amphetamine Specific 10 100 45 5 300 Wash buffer 100 30 100 
Amphetamine Ultra 10 100 45 5 300 Wash buffer 100 30 100 
Benzylpiperazine 20 50 45 5 300 Wash buffer 150 30 50 
Ketamine 20 100 45 5 300 Wash buffer 100 30 100 
Methylphenidate 20 100 45 5 300 Wash buffer 100 30 100 
Methamphetamine/MDMA 20 100 45 5 300 Wash buffer 100 30 100 
Mephentermine 20 180 45 5 300 Wash buffer 150 30 50 
Randox  
MDPV 50 75 60 6 300 Wash buffer 125 20 100 
Mephedrone/Methcathinone 25 100 60 6 300 Wash buffer 125 20 100 
OraSure  
PCP 50a 50 30 6 300 DI water 100 30 100 
Cotinine 10 100 30 6 300 DI water 100 30 100 
Amphetamine Specific 25 100 30 6 300 DI water 100 30 100 
Methamphetamine 25 100 30 6 300 Di water 100 30 100 
a 50 µL OraSure Pre-Buffer added to wells after samples were dispensed. 
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Appendix 4: Cross-Reactivity Data for ELISAs 
Cross-Reactivity Data for Immunoassays Targeting Amphetamine 
 Neogen  Amphetamine Amphetamine Specific Amphetamine Ultra 
Drug C50
b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C50b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C50b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
(+)-Amphetamine 50 100 200 50 100 100 50 100 10 
(±)-Methamphetamine < 10 > 500 10 > 10,000 < 0.5 > 10,000 < 10 > 500 15 
2C-E > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-DOET > 10,000 < 0.5 > 10,000 5,000 1 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-DOM > 10,000 < 0.5 > 10,000 5,000 1 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-TMA > 10,000 < 0.5 > 10,000 2,500 2 10,000 > 10,000 < 0.5 > 10,000 
(±)-MDA 1,250 4 5,000 78 64 100 2,500 2 7,000 
(±)-MDEA 156 32 625 > 10,000 < 0.5 > 10,000 313 16 1,000 
(±)-MDMA 156 32 1,250 > 10,000 < 0.5 > 10,000 625 8 2,500 
(±)-Ethylamphetamine < 10 > 500 < 10 > 10,000 < 0.5 > 10,000 < 10 > 500 19 
(±)-MDPV > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Mephedrone > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000   < 0.5 > 10,000 
(±)-Cathinone 2,500 2 10,000 > 10,000 < 0.5 > 10,000 10,000    0.5 > 10,000 
(±)-Methcathinone 1,250 4 5,000 > 10,000 < 0.5 > 10,000 4,250 1 4,500 
(±)-Methylone > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-4-MEC 10,000 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Flephedrone 1,250 4 > 10,000 > 10,000 < 0.5 > 10,000 10,000    0.5 > 10,000 
(±)-Butylone > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
mCPP 156 32 625 > 10,000 < 0.5 > 10,000 156 32 1,000 
(±)-Methedrone 10,000 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
5-MeO-DiPT > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-DOB 10,000 0.5 > 10,000 > 10,000 < 0.5 > 10,000 10,000 0.5 > 10,000 
2C-B > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
DMT 5,000 1 > 10,000 > 10,000 < 0.5 > 10,000 5,000 1 > 10,000 
BZP 5,000 1 > 10,000 > 10,000 < 0.5 > 10,000 3,000 1.67 10,000 
AMT 625 8 4,000 < 156 > 32 156 1,250 4 4,500 
2C-I > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
2C-T-7 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
TFMPP 2,500 2 10,000 > 10,000 < 0.5 > 10,000 2,500 2 > 10,000 
2C-T-4 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.5 > 10,000 
a Concentration of the drug that produces an absorbance reading equivalent to the 25 ng/mL cut-off of the targeted analyte. 
b Concentration of the drug that produces an absorbance reading equivalent to the 50 ng/mL cut-off of the targeted analyte. 
Analytes demonstrating high cross-reactivity are highlighted and bolded. 
The target analytes for each assay are italicized and bolded. 
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Appendix 4: Cross-Reactivity Data for ELISAs 
Cross-Reactivity Data for Immunoassays Targeting Amphetamine 
 
Immunalysis OraSure  
Amphetamine Amphetamine Specific 
Drug C25
a 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C50b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
(+)-Amphetamine 25 100 18 50 100 70 
(±)-Methamphetamine > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
2C-E > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-DOET > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-DOM 10,000   0.25 6,750 > 10,000 < 0.5 > 10,000 
(±)-TMA 5,000 0.5 6,750 > 10,000 < 0.5 > 10,000 
(±)-MDA < 10 > 250 < 10 56 89 64 
(±)-MDEA 7,000 0.36 6,500 > 10,000 < 0.5 > 10,000 
(±)-MDMA 5,000 0.5 4,250 > 10,000 < 0.5 > 10,000 
(±)-Ethylamphetamine > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-MDPV > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Mephedrone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Cathinone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Methcathinone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Methylone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-4-MEC > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Flephedrone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Butylone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
mCPP > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-Methedrone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
5-MeO-DiPT > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
(±)-DOB > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
2C-B > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
DMT > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
BZP > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
AMT 30 83 20 43 116 48 
2C-I > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
2C-T-7 > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
TFMPP > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
2C-T-4 > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 
a Concentration of the drug that produces an absorbance reading equivalent to the 25 ng/mL cut-off of targeted analyte. 
b Concentration of the drug that produces an absorbance reading equivalent to the 50 ng/mL cut-off of targeted analyte. 
Analytes demonstrating high cross-reactivity are highlighted and bolded. 
The target analytes for each assay are italicized and bolded. 
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Cross-Reactivity Data for Immunoassays Targeting Methamphetamine 
 Immunalysis Neogen OraSure Methamphetamine Methamphetamine/MDMA Methamphetamine 
Drug C25
a 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C25a 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C10b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
(+)-Methamphetamine 25 100 35 25 100 50 10 100 10 
(±)-Amphetamine > 10,000   < 0.25 > 10,000 4,000 0.63 6,750 2,500 0.4 1,250 
2C-E > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-DOET > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-DOM > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-TMA > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-MDA 5,000 0.5 6,000 1,250 2 2,000 625 2 500 
(±)-MDEA 35 71 40 156 16 313 10 100 < 10 
(±)-MDMA < 10 > 250 10 15 167 25 < 10 > 100 < 10 
(±)-Ethylamphetamine 80   31 100 156 16 600 15 67 < 10 
(±)-MDPV > 10,000   < 0.25 > 10,000 > 10,000 < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Mephedrone 1,250   2 2,500 2,500 1 9,000 40 25 20 
(±)-Cathinone > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Methcathinone 5,000   0.5 5,000 5,000   0.5 > 10,000 300 3.33 150 
(±)-Methylone 2,500   1 4,000 5,000   0.5 > 10,000 150 6.67 < 150 
(±)-4-MEC 1,250   2 1,250 2,500   1 > 10,000 40 25 20 
(±)-Flephedrone 10,000   0.25 10,000 2,500   1 > 10,000 450 2.22 250 
(±)-Butylone 10,000   0.25 10,000 5,000   0.5 > 10,000 300 3 175 
mCPP > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Methedrone 3,500   0.71 3,500 1,250   2 7,000 150 6.67 60 
5-MeO-DiPT > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-DOB > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
2C-B > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
DMT > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
BZP > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
AMT > 10,000   < 0.25 > 10,000 5,000   0.5 > 10,000 2,500 0.4 2,000 
2C-I > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
2C-T-7 > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
TFMPP > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
2C-T-4 > 10,000   < 0.25 > 10,000 > 10,000   < 0.25 > 10,000 > 10,000 < 0.1 > 10,000 
a Concentration of the drug that produces an absorbance reading equivalent to the 25 ng/mL cut-off of the targeted analyte. 
b Concentration of the drug that produces an absorbance reading equivalent to the 10 ng/mL cut-off of the targeted analyte. 
Analytes demonstrating high cross-reactivity are highlighted and bolded. 
The target analytes for each assay are italicized and bolded. 
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Cross-Reactivity Data for Additional Neogen Assays 
 Neogen 
 Benzylpiperazine Ketamine Methylphenidate Mephentermine 
Drug C25
a 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C50b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C10c 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C10c 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
(±)-Amphetamine > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Methamphetamine 10,000   0.25 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 250 4 400 
2C-E > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-DOET > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-DOM > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-TMA > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-MDA > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 10,000 0.1 > 10,000 
(±)-MDEA 9,000   0.25 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 1,250 0.80 7,000 
(±)-MDMA 10,000   0.25 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 200 5 750 
(±)-Ethylamphetamine > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 1,750 0.60 3,000 
(±)-MDPV > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Mephedrone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Cathinone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Methcathinone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Methylone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-4-MEC > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Flephedrone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Butylone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
mCPP > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-Methedrone > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
5-MeO-DiPT > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
(±)-DOB > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
2C-B > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
DMT 5,000   0.50 5,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
BZP 25   100 35 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
AMT > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
2C-I > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
2C-T-7 > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
TFMPP > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
2C-T-4 > 10,000   < 0.25 > 10,000 > 10,000 < 0.5 > 10,000 > 10,000 < 0.1 > 10,000 > 10,000 < 0.1 > 10,000 
a Concentration of the drug that produces an absorbance reading equivalent to the 25 ng/mL cut-off of the targeted analyte. 
b Concentration of the drug that produces an absorbance reading equivalent to the 50 ng/mL cut-off of the targeted analyte. 
c Concentration of the drug that produces an absorbance reading equivalent to the 10 ng/mL cut-off of the targeted analyte. 
Analytes demonstrating high cross-reactivity are highlighted and bolded. 
The target analytes for each assay are italicized and bolded. 
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Appendix 4: Cross-Reactivity Data for ELISAs 
Cross-Reactivity Data for Additional Randox and OraSure Assays 
 Randox OraSure 
 MDPV Mephedrone/Methcathinone PCP Cotinine 
Drug C10
a 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C1.25b 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C20c 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
C100d 
(ng/mL) 
Cross- 
Reactivity (%) 
EC50 
(ng/mL) 
(±)-Amphetamine > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Methamphetamine > 10,000   < 0.1 > 10,000 5,000   0.0250 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
2C-E > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-DOET > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-DOM > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-TMA > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-MDA > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-MDEA > 10,000   < 0.1 > 10,000 10,000   0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-MDMA > 10,000   < 0.1 > 10,000 2,500   0.05 5,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Ethylamphetamine > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-MDPV 10   100 60 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Mephedrone > 10,000   < 0.1 > 10,000 1.25   100 2.5 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Cathinone > 10,000   < 0.1 > 10,000 1,000   0.125 3,500 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Methcathinone > 10,000   < 0.1 > 10,000 < 156 > 0.8 < 156 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Methylone 5,000   0.2 > 10,000 < 156 > 0.8 < 156 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-4-MEC 7,500   0.13 > 10,000 < 156 > 0.8 < 156 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Flephedrone > 10,000   < 0.1 > 10,000 < 156 > 0.8 < 156 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Butylone 156   6.4 900 < 156 > 0.8 < 156 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
mCPP > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-Methedrone > 10,000   < 0.1 > 10,000 < 156 > 0.8 < 156 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
5-MeO-DiPT > 10,000   < 0.1 > 10,000 5,000   0.025 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
(±)-DOB > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
2C-B > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
DMT > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
BZP > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
AMT > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
2C-I > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
2C-T-7 > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
TFMPP > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
2C-T-4 > 10,000   < 0.1 > 10,000 > 10,000   < 0.0125 > 10,000 > 10,000   < 0.2 > 10,000 > 10,000   < 1 > 10,000 
a Concentration of the drug that produces an absorbance reading equivalent to the 10 ng/mL cut-off of the targeted analyte. 
b Concentration of the drug that produces an absorbance reading equivalent to the 1.25 ng/mL cut-off of the targeted analyte. 
c Concentration of the drug that produces an absorbance reading equivalent to the 20 ng/mL cut-off of the targeted analyte. 
d Concentration of the drug that produces an absorbance reading equivalent to the 100 ng/mL cut-off of the targeted analyte. 
Analytes demonstrating high cross-reactivity are highlighted and bolded. 
The target analytes for each assay are italicized and bolded. 
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Appendix 5: Dynamic MRM MS Parameters 
No. Drug Transitionsa CE (V) Fragmentor (V) tR (min) Internal Standard 
1 DOB 274.01 à  256.9 14 100 3.846 d6-Amphetamine 
  274.01 à 228.9 10    
2 DOET 224.3 à  207 5 85 4.547 d6-Amphetamine 
  224.3 à 91 49    
3 DOM 210.3 à  193.1 5 75 3.538 d6-Amphetamine 
  210.3 à 165 13    
4 TMA 226.3 à  209 5 80 2.075 d6-Amphetamine 
  226.3 à 91 45    
5 2C-B 260.01 à  242.9 4 90 3.403 d5-MDMA 
  260.01 à 227.9 6    
6 2C-E 210.3 à  193 5 80 4.119 d5-MDMA 
  210.3 à 163 25    
7 2C-I 308.1 à  290.9 9 90 3.906 d5-MDMA 
  308.1 à 91 49    
8 2C-T-4 256.4 à  239 5 90 4.675 d5-MDMA 
  256.4 à 197 17    
9 2C-T-7 256.4 à  239 9 85 4.959 d5-MDMA 
  256.4 à 166.9 29    
10 MDA 180.1 à  163 4 70 1.658 d6-Amphetamine 
  180.1 à 105 20    
11 MDEA 208.14 à  163 8 90 2.220 d5-MDMA 
  208.14 à 105 24    
12 MDMA 194.1 à  163 8 85 1.849 d5-MDMA 
  194.1 à 105 24    
13 Amphetamine 136.11 à  91 16 75 1.490 d6-Amphetamine 
  136.11 à 119 4    
14 Methamphetamine 150.13 à  91 16 80 1.715 d5-MDMA 
  150.13 à 119 4    
15 Ethylamphetamine 164.11 à  91 20 85 2.093 d5-MDMA 
  164.11 à 119 8    
16 MDPV 276.3 à  126 25 130 3.383 d3-Methylone 
  276.3 à 135 25    
17 Mephedrone 178.25 à  160 10 85 2.123 d3-Mephedrone 
  178.25 à 144 30    
18 Cathinone 150.2 à  132 10 80 1.031 d3-Mephedrone 
  150.2 à 117 22    
19 Methcathinone 164.23 à  146 10 85 1.196 d3-Mephedrone 
  164.23 à 130 34    
20 Methedrone 194.25 à  176 10 80 1.745 d3-Mephedrone 
  194.25 à 161 18    
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No. Drug Transitionsa CE (V) Fragmentor (V) tR (min) Internal Standard 
21 4-MEC 192.28 à  174.1 10 95 2.482 d3-Mephedrone 
  192.28 à 145 18    
22 Flephedrone 182.21 à  164 10 85 1.422 d3-Mephedrone 
  182.21 à 148 34    
23 Methylone 208.24 à  160 14 80 1.397 d3-Methylone 
  208.24 à 132 26    
24 Butylone 222.26 à  174 14 95 2.035 d3-Methylone 
  222.26 à 204 10    
25 BZP 177.11 à  91 20 100 0.589 d7-BZP 
  177.11 à 65 50    
26 DBZP 267.21 à  91 32 125 3.520 d7-BZP 
  267.21 à 175 12    
27 mCPP 197.11 à  153.9 20 120 2.878 d4-TFMPP 
  197.11 à 118 36    
28 TFMPP 231.11 à  188 20 125 3.826 d4-TFMPP 
  231.11 à 118 44    
29 AMT 175.2 à  158 9 75 2.037 d6-Amphetamine 
  175.2 à 143 25    
30 DMT 189.11 à  58.1 8 85 1.775 d5-MDMA 
  189.11 à 144 16    
31 5-MeO-DMT 219.3 à  58.1 9 85 1.955 d5-MDMA 
  219.3 à 174 9    
32 5-MeO-DiPT 275.4 à  174 17 100 3.627 d5-MDMA 
  275.4 à 114.1 13    
33 d6-Amphetamine (IS) 142.25 à  93 13 75 1.470 - 
  142.25 à 125.1 5    
34 d5-MDMA (IS) 199.29 à  165 9 90 1.839 - 
  199.29 à 107 25    
35 d3-Mephedrone (IS) 181.27 à  163 9 90 2.115 - 
  181.27 à 148 21    
36 d3-Methylone (IS) 211.21 à  163 13 85 1.390 - 
  211.21 à 135 29    
37 d7-BZP (IS) 184.11 à  98.1 21 105 0.562 - 
  184.11 à 70.1 57    
38 d4-TFMPP (IS) 235.11 à  190 21 125 3.815 - 
  235.11 à 46.1 21    
a Quantifying transition in bold, qualifying transition in normal text.  
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Appendix 6: Matrix Effects, Recovery, and Process Efficiency 
  Matrix Effects Recovery Process Efficiency 
  LOW HIGH LOW HIGH LOW HIGH 
Compound meana %RSD mean %RSDb mean %RSD mean %RSD mean %RSD mean %RSD 
BZP 110.5 8.2 105 7.6 85.1 7.6 86.8 6 94 7.3 91.1 5.9 
Cathinone 75.1 11.3 99.6 9.6 97.5 12.7 84.2 7.4 73.2 12.4 83.9 7.2 
Methcathinone 99.3 12.4 93 7.4 74.5 13.3 83.3 6.5 73.9 12.9 77.5 6.4 
Methylone 82.4 10.8 86.1 7.2 84.9 11 88.4 6 70 10.7 76.1 5.9 
Flephedrone 77.5 10.2 74.8 4.2 82.6 10.1 82.8 4.1 64 9.8 61.9 4.1 
Amphetamine 92.4 10.5 85 7.8 83.9 10.2 90.2 6 77.5 9.8 76.7 5.9 
MDA 87.7 7.4 85.8 6.6 95.8 8.8 90.3 7.2 84 8.6 77.5 7.2 
Methedrone 94.1 11.9 94.8 5.5 80.8 11.4 82.8 4.8 76.1 11 78.5 4.7 
Methamphetamine 97.6 12.1 82.4 4.7 88.8 10.7 87.6 6.9 86.7 10.2 72.1 6.9 
DMT 64.2 8.7 90.3 11.7 125.3 14.1 99.4 9.5 80.4 13.9 89.7 9.3 
MDMA 92.2 11.6 88.5 6.6 85.3 10.6 82.6 7.7 78.6 10.3 73.1 7.6 
5-MeO-DMT 52.9 12.9 60.6 12.7 127.4 16.2 106.1 11.5 67.3 15.9 64.3 11.3 
Butylone 98.9 12.4 90.5 5.5 80.8 12.1 80.9 4.5 79.8 11.8 73.2 4.4 
AMT 67.5 9.5 68.6 13.5 128.5 8.5 104.5 10.2 86.8 8.2 71.7 10 
TMA 85 9.1 84.9 6.9 81 9 89.5 7 68.8 8.7 76 7 
Ethylamphetamine 102.2 12.3 90.3 5 88.7 11.4 83.4 8.6 90.6 11 75.3 8.6 
Mephedrone 78.6 10.6 78 6.5 81.6 9.7 84.5 5.6 64.1 9.3 65.9 5.5 
MDEA 118.8 13.8 88.4 7.7 84.8 13.4 80.7 5.7 100.7 13 71.4 5.5 
4-MEC 112.7 13.5 88.1 7.7 82.7 13.1 83.5 6.6 93.2 12.7 73.5 6.5 
mCPP 84.7 11.1 90.1 8.1 96.5 11.8 85.4 6.5 81.7 11.5 76.9 6.4 
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  Matrix Effects Recovery Process Efficiency 
  LOW HIGH LOW HIGH LOW HIGH 
Compound meana %RSD mean %RSDb mean %RSD mean %RSD mean %RSD mean %RSD 
MDPV 109.9 14.5 106.7 8.5 80.1 15 81.4 6.9 88 14.6 86.9 6.8 
2C-B 89.2 9.8 95 6 84.2 10.4 81.7 5.1 75.1 10.1 77.6 5 
DBZP 118.2 15.6 120.6 10.5 84.6 14.9 87.4 8.1 99.9 14.4 105.3 7.9 
DOM 92.5 11.6 72.4 12.8 88.3 11.3 84.7 10.5 81.8 10.9 61.3 10.4 
5-MeO-DiPT 70.7 13.9 70.9 14.5 103.6 16.9 100.2 11.6 73.2 16.6 71 11.4 
DOB 70.4 10 85.6 7.7 96.7 10.2 90.1 5.9 68.1 9.9 77.1 5.8 
TFMPP 86.8 10.2 76.5 6.1 91.4 8.6 85.7 5.7 79.3 8.2 65.6 5.7 
2C-I 88.4 9.8 88 8 88.4 10.8 79.7 6.1 78.2 10.5 70.2 6 
2C-E 87.4 11.6 95.7 8.3 87.4 11.1 76 6.2 76.4 10.7 72.8 6.1 
DOET 93.6 11.7 79 7.4 80.3 11.3 80.5 5.7 75.2 10.9 63.6 5.6 
2C-T-4 92.2 11.3 111.1 9.5 71.8 12.7 69.5 9.9 66.2 12.4 77.2 9.8 
2C-T-7 106.7 12.1 123.8 10.2 68.6 13.5 67.3 8.2 73.2 13.2 83.3 8.1 
a Data in %, see Equation 1 for details. 
b Data in %, see Equation 2 for details. 
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Appendix 7: Processed Sample Stability at Two Concentrations 
  LOW Based on Regression Line HIGH Based on Regression Line 
Drug Slope Intercept 
Initial Final  
∆ (%) Slope Intercept 
Initial  Final  
∆ (%) 
 (0 h) (28 h) (2 h) (30 h) 
BZP  -109 40404 40404 37357 -7.5 963 611205 613130 640084 4.4 
Cathinone -68 19648 19648 17745 -9.7 -216 432246 431814 425765 -1.4 
Methcathinone -85 32986 32986 30594 -7.3 -1605 1100493 1097282 1052334 -4.1 
Methylone  -160 52341 52341 47857 -8.6 -2126 1520949 1516697 1457172 -3.9 
Flephedrone -97 35323 35323 32603 -7.7 -677 703464 702111 683162 -2.7 
Amphetamine -88 17547 17547 15076 -14.1 2926 396416 402268 484202 20.4 
MDA -176 41489 41489 36574 -11.8 -1090 633973 631793 601267 -4.8 
Methedrone -116 40789 40789 37544 -8 -4361 900848 892125 770006 -13.7 
Methamphetamine -95 26058 26058 23405 -10.2 -1979 510413 506456 451055 -10.9 
DMT 177 7223 7223 12188 68.7 4125 579902 588152 703649 19.6 
MDMA  -152 45195 45195 40935 -9.4 -7218 1323056 1308620 1106522 -15.4 
5-MeO-DMT 213 7119 7119 13091 83.9 7709 970115 985533 1201385 21.9 
Butylone -157 49644 49644 45254 -8.8 -4301 1230952 1222351 1101931 -9.9 
AMT 301 6056 6056 14491 139.3 2102 42776 46979 105821 125.3 
TMA 294 23588 23588 31814 34.9 -626 591243 589990 572450 -3 
Ethylamphetamine -121 35386 35386 32012 -9.5 -2922 924730 918886 837070 -8.9 
Mephedrone  -111 42074 42074 38969 -7.4 -1015 1006374 1004344 975927 -2.8 
MDEA -159 63807 63807 59349 -7 -4413 2638023 2629198 2505648 -4.7 
4-MEC -77 35130 35130 32968 -6.2 -2118 1550957 1546722 1487432 -3.8 
mCPP -7 9123 9123 8925 -2.2 -26 322319 322268 321548 -0.2 
MDPV -101 29138 29138 26307 -9.7 -3761 1674238 1666716 1561408 -6.3 
2C-B 52 18695 18695 20154 7.8 -594 397233 396045 379407 -4.2 
DBZP -34 9617 9617 8654 -10 -2004 1019820 1015812 959697 -5.5 
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  LOW Based on Regression Line HIGH Based on Regression Line 
Drug Slope Intercept 
Initial Final  
∆ (%) Slope Intercept 
Initial  Final  
∆ (%) 
 (0 h) (28 h) (2 h) (30 h) 
DOM -317 125746 125746 116857 -7.1 -5532 3058967 3047903 2893013 -5.1 
5-MeO-DiPT 319 12644 12644 21575 70.6 19176 2280395 2318747 2855675 23.2 
DOB -48 32652 32652 31311 -4.1 -1342 965105 962421 924851 -3.9 
TFMPP  5 21625 21625 21756 0.6 -374 420297 419548 409064 -2.5 
2C-I 12 39936 39936 40270 0.8 -898 1369695 1367898 1342740 -1.8 
2C-E -301 95824 95824 87387 -8.8 -3681 3256687 3249326 3146272 -3.2 
DOET -366 168366 168366 158121 -6.1 -7521 4739575 4724532 4513933 -4.5 
2C-T-4 30 48780 48780 49632 1.7 -2993 2486121 2480135 2396325 -3.4 
2C-T-7 -18 40176 40176 39671 -1.3 3206 2418269 2424682 2514458 3.7 
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Appendix 8: Summary of Precision and Accuracy Data for at Four Concentrations 
  Repeatability (%RSD) Intermediate Precision (%RSD) Accuracy, Bias (%) 
Analyte LLOQ 
LO
W 
ME
D 
HIG
H 
LLO
Q 
LO
W 
ME
D 
HIG
H 
LLO
Q 
LO
W 
ME
D 
HIG
H 
BZP 3.4 4.2 4.3 6.6 4 5.4 5 6.6 -7.7 -1 2 0.2 
Cathinone 13.3 9.3 11.9 10.8 15.3 9.9 11.9 12.3 -9.9 -9.9 -2.9 0.6 
Methcathinone 7 5.5 11 12.5 8.6 6.8 11 13.9 -5.7 -10 -4.9 0.6 
Methylone 6.5 6 5.4 6.1 6.9 6.8 5.9 6.1 -10.2 -2.2 0.2 -4.6 
Flephedrone 6.8 7.3 2.9 8.2 7.4 8 3.1 8.2 -13.2 -8 -4.4 -6.7 
Amphetamine 4.9 4.8 3.8 11.8 6.1 5.7 3.9 11.9 -6.5 -0.6 4.3 2.6 
MDA 5.2 5.4 12.7 11.9 6.5 6.3 12.8 11.7 -6.7 2.3 0.8 -6.2 
Methedrone 4.1 3.4 4.8 12.5 6.5 4.8 5.1 12.2 -2.1 -4.2 -0.7 -2.7 
Methamphetamin
e 5.4 5.5 7.7 11.4 7.9 6.4 7.7 11.5 -4.8 -1.5 2 -6.6 
DMT 3.4 4.4 4.2 4 4.9 5.4 4.5 4.1 -3.5 -1.7 5.1 27.5 
MDMA 5.4 5.8 4 9.7 5.9 6.3 4.4 9.7 -6 -0.4 3 1.9 
5-MeO-DMT 3.6 4.2 3.8 3.2 5.1 5.2 4 3.3 -7.3 2.6 18.5 60 
Butylone 4.2 4.3 5.2 13.6 6.2 5.3 5.4 13.6 -6.6 0.3 -0.2 -5.3 
AMT 3 4.4 3.8 6.7 4.2 5.4 4.1 6.9 12.1 -1.5 16.7 -23.6 
TMA 3.2 4.2 5.1 6 4.5 5.1 5.5 6.2 4.9 4.2 -12.9 -14.9 
Ethylamphetamin
e 9.2 7 6.8 6.1 10.6 7.8 7.1 6.2 -0.2 0.1 0.7 5 
Mephedrone 4.7 5.6 3.2 8.5 5.3 6.3 3.6 8.5 -9.5 -5 -2 -3.7 
MDEA 9.3 7.1 13.1 5.4 11.9 7.9 13.1 6.4 0.6 -3.9 -1.8 0.6 
4-MEC 4.3 6.6 13.8 11.3 6.5 7.5 13.8 12 3.1 -6.9 -2.9 2.8 
mCPP 3.6 8.8 13.6 12.1 6.7 10.6 13.6 12.1 9.6 0.9 0.2 8.8 
MDPV 8.7 8.7 12.4 7.8 10.4 9.1 12.4 8.8 8.3 -5.1 -4.8 5.8 
2C-B 14.6 5.7 7.2 7.6 15.5 6.7 7.3 7.7 -9.9 -3.5 -5.3 -2.1 
DBZP 2.8 3.7 4.4 4.9 3.9 4.6 4.7 5 20.3 16.6 1.2 4.8 
DOM 11.3 6.3 12.5 13.7 13.8 7.1 13 13.7 -3.7 -0.2 -3.1 -10.8 
5-MeO-DiPT 3.5 4.2 4.4 4.9 5 5.2 4.7 5 -6.1 3.2 0.6 4.6 
DOB 13.6 7.7 12.8 11.1 14.7 8.1 13 11.1 -10.7 1.2 -1.8 -11.9 
TFMPP 2.1 3.8 4.4 7.2 4.4 4.6 4.6 7.4 -8.5 -2.9 0.8 -0.5 
2C-I 19.1 9.9 12.3 11.9 19.5 10.4 12.6 11.9 -13.3 2.8 -3 -9.5 
2C-E 12.5 7 5.7 15 12.7 7.3 6 14.9 -6.3 -3.6 -2.1 -0.4 
DOET 3.6 4 5.6 6.7 5.1 4.9 6 6.8 -7.4 9.1 -21.2 -22.8 
2C-T-4 17.1 10.9 11.8 14.2 17.3 11.4 13.6 14.2 1.9 -2.9 -12.9 -4.1 
2C-T-7 18 10.1 11.2 9.2 18.4 10.5 12.5 9.5 1.2 -5 -11.1 -3.2 
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Appendix 9: Blind Spiked Sample Analysis by ELISA 
  Immunalysis  Neogen  Randox  OraSure  
Sample Amp Meth Amp 
AMP 
Specific 
Amp 
Ultra BZP Ketamine MPD 
Meth/ 
MDMA MPT MDPV 
Meph/ 
Mcath  PCP Cotinine 
Amp 
Specific Meth 
Sample 01 - - - - - - - - - - - + - + - - 
Sample 02 - - - - - - - - - - - + - + - - 
Sample 03 - + + - + - - - ± - ± ± - + - + 
Sample 04 - + + - + - - - ± - ± - - + - + 
Sample 05 - - - - - - - - - - - - - + - - 
Sample 06 - + + - + - - - + - - + - + - + 
Sample 07 - + + - + - - - + - - + - + - + 
Sample 08 - + + - + - - - + ± ± - - + - + 
Sample 09 - + + - + ± - - + ± - - - + - + 
Sample 10 - - - - - - - - - - - + - + - + 
Sample 11 + - + + + - - - - - - - - + + - 
Sample 12 - - - - - - - - - - - + - + - ± 
Sample 13 - - - - - - - - - - - - - + - - 
Sample 14 - - - - - - - - - - + + - + - + 
Sample 15 + + + + + - - - ± - ± + - + + + 
Sample 16 - - - - - - - - - - - - - + - - 
Sample 17 - - - - - - - - - - - - - + - - 
Sample 18 - - - - - - - - - - - - - + - - 
Sample 19 - - - - - - - - - - - - - + - - 
Sample 20 - - - - - - - - - - - - - + - - 
Sample 21 - - - - - - - - - - - + - + - - 
Sample 22 - - - - - - - - - - - + - + - - 
 
 
126 
Appendix 10: PBSO Sample Analysis by ELISA 
  Immunalysis  Neogen  Randox  OraSure  
Sample Amp Meth Amp 
AMP 
Specific 
Amp 
Ultra BZP Ketamine MPD 
Meth/ 
MDMA MPT MDPV 
Meph/ 
Mcath  PCP Cotinine 
Amp 
Specific Meth 
07-001 - - - - - - - - - - - - - - - - 
11-001 - - - - - - - - - - - - - - - - 
11-002 - - - - - - - - - - - - - + - - 
12-001 - - - - - - - - - - - - - + - - 
12-002 - - - - - - - - - - - - - + - - 
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